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COST OF CARE FOR HOSPITALIZED PATIENTS WITH PULMONARY 
MYCOBACTERIAL DISEASES IN THE UNITED STATES 
Mary Elizabeth Wells Allen 
November 30, 2016 
Background: Pulmonary mycobacterial diseases describe both 
tuberculosis (TB) and nontuberculous mycobacteria (NTM).  Few data are 
available measuring the cost burden of mycobacterial diseases on the 
national level.  The purpose of this study was to evaluate the cost burden 
and measure emerging trends in hospitalization of pulmonary TB and 
NTM in the US from 2001 through 2012.  
Methods: This study was a retrospective community based cost analysis 
of hospitalized patients with a principal diagnosis of pulmonary 
mycobacterial diseases from 2001 through 2012.  Data for pulmonary TB 
and NTM were retrieved from the Healthcare Cost and Utilization Project 
(HCUP), US Department of Health and Human Services.  The statistical 
significance of observed trends of NTM and TB national hospital costs 
 vi 
 
was calculated using Poisson log-linear regression.  
Results: A total of 20,049 hospital admissions were reported for 
pulmonary NTM and 69,257 for pulmonary TB in the US from 2001 
through 2012.  The total associated cost of these admissions was 
$903,767,292 for pulmonary NTM and $2,078,113,317 for pulmonary TB. 
During the study period, the national hospital costs of pulmonary NTM 
increased at a statistically significant rate in the US over each year 
(P=0.001).  However, no such increase was found for national hospital 
costs of pulmonary TB.  
Conclusion: The national hospital cost of NTM management is 
increasing.  These results emphasize the importance of continued 
research in pulmonary NTM in order to improve current guidelines in 
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Mycobacterial diseases describe the infectious processes caused 
by one of many pathogens from the Mycobacteriaceae genus.  The most 
notable of these pathogens is Mycobacterium tuberculosis (TB), which 
remains an important worldwide public health challenge.  Another 
important pathogen is Nontuberculous mycobacteria (NTM) which has 
become an emerging public health problem.  Both TB and NTM have 
many clinical presentations, but the most common manifestation of 
disease is pulmonary and both diseases manifest with similar 
symptomology.  Both diseases are also associated with significant 
morbidity and mortality.  Despite similarities, TB and NTM differ 
dramatically in terms of contemporary public health challenges.  Recent 
advances in laboratory diagnostic techniques, the improvement of 
treatment regimens, and improvements in disease surveillance and control 
have allowed many developed countries to reduce the burden of TB.  This 
is the case in the US in which TB related mortality has been in decline.  
Still, major challenges in TB care persist, and include the drug resistance 
and co-infection with HIV disease.  Although TB in the developed world 
still impacts key populations, the global TB epidemic which have been 
shown to disproportionately affect developing countries in Asia and Africa.  
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NTM, however, represents an emerging public health problem with 
increasing incidence and associated death rates that are projected to 
continue to increase in coming decades.  The cost of care for both 
diseases is likely to reflect these challenges.  The purpose of this study is 
to evaluate the cost burden of pulmonary TB and NTM in the US as well 
as to identify emerging trends using hospitalization data obtained from the 
Healthcare Cost and Utilization Project (HCUP), a database from the US 
Department of Health and Human Services.  Data was collected between 
the years 2001 and 2012 in order to show changes over time for both 
diseases.  The goal of this study was to demonstrate the clinical 
importance and cost of managing mycobacterial diseases in order to 
identify important considerations for future research as well as provide 













CHAPTER 1: OVERVIEW OF MYCOBACTERIAL 
DISEASE 
Mycobacterium is defined as any one of the variety of both 
pathogenic and nonpathogenic organisms that are from the genus of the 
Mycobacteriaceae family.  Currently consisting of nearly two hundred 
currently identified species, mycobacteria have several important and 
distinct characteristics.  For starters, mycobacterium species are aerobic, 
which means these organisms rely on oxygen for survival.  This also has 
important clinical implications for mycobacterial disease, which describes 
any disease process caused by pathogenic mycobacterium organisms.  
Pulmonary disease is the most common manifestation of mycobacterial 
diseases given the high availability of oxygen in the lungs, and symptoms 
appear the same in most cases regardless of the pathogen.  However, 
mycobacterial diseases can occur at most any location.  Mycobacterium 
organisms are slow growing, which impacts diagnostics given that cultures 
sometimes take weeks to form colonies in a laboratory setting.  The slow 
growth of mycobacteria also has important clinical implications that can 
lead to a sometimes mild and chronic form of disease.  Mycobacterium 
species are characterized by particularly thick cell walls that contribute to 
survival in different environments as well as resistance to many antibiotic 
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therapies.  Drugs used to treat mycobacterial diseases often involve 
alternative pathways of cell entry, as cell wall penetration is a common 
mechanism of action for many types of antibiotics.  This results in fewer 
therapeutic options available to treat mycobacterial disease, and therapy 
is much longer in duration as compared to most other infections.  Also, the 
cell wall is constructed of a waxy, lipid material that repels the dyes used 
in Gram staining resulting in a distinct appearance referred to acid-
fastness. This feature is unique to mycobacteria and helps support 
diagnostics given the slow culture growth of these organisms.  
Mycobacteria are referred to as bacillus, which is a term used to describe 
rod-shaped organisms.  Their unique appearance also contributes to the 
recognition of mycobacteria in a laboratory setting.1,2  Infections caused by 
mycobacterium species tend to be chronic, difficult to diagnose, involve 
long complicated treatment courses, and represent a significant source of 
morbidity and mortality in the US and the world.3  
Mycobacterium tuberculosis 
Mycobacterium tuberculosis (TB) is the most common 
mycobacterium species that causes disease in humans.  Discovered by 
German scientist Robert Koch in 1882 as part of the M. tuberculosis 
complex of organisms, TB includes diseases caused by M. africanum, M. 
bovis, M. microti, and M. canett, and M. tuberculosis.4  TB represents an 




TB has been believed to be a source of human disease for 
thousands of years, but the origin and pathogenic history of TB is not well 
understood.  Several DNA studies of remains from humans and animals 
have attempted to piece together the epidemiological history of disease in 
world populations as well as the genetic evolution of M. tuberculosis 
organisms.  For example, TB has been isolated in human remains 
collected from thousands of years ago from locations on both sides of the 
Atlantic Ocean.  Evidence of the presence of TB in the western 
hemisphere consists of the discovery of the disease in a human mummy 
discovered in Peru from around 6,000 years ago.5  This finding was similar 
to those isolated from Egyptian mummies.6  Another discovery was made 
in the remains of an extinct bison estimated to be around 17,000 years old 
in North America.  Identification of DNA fragments was conducted using 
the spoligotyping technique with direct DNA sequence determination, 
suggesting that cattle may have been one of the earliest vectors for 
disease transmission.7   In the eastern hemisphere, a study of samples 
obtained from ancient Syria identified the presence of TB in human 
remains; however, TB was not isolated from animal remains from the 
same site.  This evidence suggests the presence of human disease prior 
to animals following domestication.8  Additionally, several studies have 
identified TB in the remains of humans from Europe, Asia and Africa.  
Many of these reports and subsequent DNA analyses can be found in the 
published work from Albert Zink and colleagues.  In numerous studies, 
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Zink has taken mummified and skeletal remains from different time 
periods and compared them with genetic material of TB obtained from 
present day samples.  Comparing historical samples from southern 
Germany (1,400–1,800 AD), Hungary (600–1,700 AD),9,10 and Egypt 
(3,500–500 BC), Zink and researchers were able to further characterize 
mycobacterial DNA samples obtained from ancient Egypt.11 
In the more recent history, TB is well described as a source of 
significant morbidity and mortality for centuries in Europe.  Referred to by 
a number of names including consumption, the robber of youth, and the 
white plague, the disease was well described in both medicine and 
literature of the time.  Doctors, writers and even poets described the 
characteristic features of the disease that included thin bodies secondary 
to wasting, pale complexion, and the association of the disease with the 
youth.12  In the seventeenth century, infection rates in London, England 
were reported at 1,000 per 100,000 people per year.13  During the 
eighteenth and nineteenth centuries, TB rates increased charactering the 
disease as an epidemic in Europe that disproportionately affected the 
poor.  Although history reports incidents of the wealthy becoming infected 
with the disease, they were afforded the option to travel to more suitable 
climates, comforts and access to remedies.  These options were not 
available to the poor, who were likely confined to substandard living 
conditions and subject to poor nutrition.  These factors amplified the 
impact of the disease process in this population and most likely 
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contributed to poor outcomes and an increase in death rates.14  By the 
nineteenth century, TB was attributable to 25% of all mortality in Europe.  
Interestingly, infection rates declined at the turn of the twentieth century 
prior to the discovery of anti-TB drugs.  This decrease in TB infection rates 
is believed to be a result of improvements in standards of living in cities, 
which includes housing, nutrition and rising income.15  As a result of the 
advent of anti-TB drugs coupled with public health policies focused on 
treatment and prevention, TB in the twentieth century became irrelevant.  
In fact, some experts of the time believed that TB could be eradicated like 
other infectious diseases such as smallpox.16  
At the close of the twentieth century, TB reemerged as a major 
global epidemic.  Among the factors contributing to the sharp resurgence 
in TB rates was the worldwide HIV/AIDS pandemic coupled with the onset 
of drug resistance.  TB having become a recurring global health crisis 
stimulated renewed interest in research and development in many areas 
of the disease, resulting in recent advancements in diagnostics, 
treatments, and improving the understanding of clinical and nonclinical 
factors impacting human disease.17  However, because mortality rates 
sharply declined for a time, fewer resources were diverted to new drug 
development, diagnostics and vaccine studies for several decades.  As a 
result, the medical community continues to rely upon outdated therapies 
and diagnostic technology in care settings in both developed and low 
resource countries, leaving much of the world ill equipped to address 
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emerging needs.18,19     
Clinical Features 
The natural history of TB infection begins with exposure followed by 
the onset of latent disease.  Latent TB describes the colonization of the 
organism in body.   Latent TB rarely presents with symptoms as the 
mycobacterial pathogens remain dormant until an opportunity presents 
itself to overtake a weakened immune system and multiply.  It is common 
for active infection to occur years later following a major change to the 
host’s health status, particularly the immune system.  However, the 
activation of disease sometimes occurs for no known reason, resulting in 
progression from latent to active disease being sometimes unpredictable.  
Screening for latent disease can be part of an effective prevention strategy 
by treating latent infection thus preventing the activation of disease.  
Treating latent disease can also be an important strategy in reducing 
further transmission.  Testing for dormant infection can be done using the 
tuberculin skin test (TST) or blood assay tests including the QuantiFERON 
and T-SPOT.20,21 
  The next phase in TB is the activation of disease.  Pulmonary TB 
is the most common manifestation of disease with classic symptoms 
including chronic productive cough, hemoptysis, fevers and/or chills, night 
sweats, and weight loss.  However, TB infection can occur at virtually any 
position in the body.  Atypical presentations, which is commonly referred 
to as extrapulmonary TB, describes any presentation of TB infection 
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outside of the lungs.22  In these cases, symptomology can be diverse with 
many symptoms having been described in the medical literature for each 
site of infection.  Most common extrapulmonary TB sites of infection 
include lymphadenitis, pleural space, septic arthritis, osteomyelitis, central 
nervous system, abdomen, and disseminated disease.  Extrapulmonary 
TB has become more common since the beginning of the HIV/AIDS 
pandemic, with immunosuppression associated with advanced AIDS being 
a primary risk factor.  In fact, more than half of AIDS patients develop 
extrapulmonary TB.  Further, the management of extrapulmonary TB in 
HIV infected hosts can present treatment challenges given the higher 
likelihood of drug-drug interactions, but treatment response in HIV infected 
hosts seems overall favorable without any measurable increased risk of 
infection relapse.23  
Host factors play a critical role in susceptibility to infection as well 
as disease presentation, some of which are not well understood.  Young 
adult males, for example, have been shown to have a higher likelihood of 
developing TB than other age groups and more so than females.  
Healthcare workers are another important risk group given their much 
higher likelihood of exposure, especially those working with populations 
with higher TB prevalence or in specialty clinics in which TB patients are 
being treated.  Other host factors can be explained by immune 
suppression.24  Activation of TB can occur secondary to several health 
conditions and diseases that suppress the immune system, the use of 
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certain drug therapies that suppress the immune system as part of cancer 
treatment, post-transplant therapy or immune modulation therapy such as 
antitumor necrosis factor-α (TNF-α) drugs commonly used to treat auto-
immune diseases.  Also, the presence of several underlying diseases are 
a common facilitator of active TB infection in many parts of the world such 
as pulmonary diseases, diabetes mellitus,25 and other conditions that have 
been shown to affect the immune system.  Behavioral factors can also 
play an important role such as diet and malnutrition, alcoholism, and 
smoking tobacco, the latter of which the World Health Organization (WHO) 
attributes to 20% of TB cases.26,27  Emerging science has also pinpointed 
genetic susceptibility factors, some of which are being explored for the 
purpose of developing personalized therapies and vaccines.28,29   
Transmission 
The transmission patterns of TB have remained a point of inquiry in 
historical and current studies.  The transmission of disease person to 
person is well described.  Although the highly contagious nature of TB 
pathogens allows the disease to be transmitted with only small amounts of 
airborne respiratory fluids propelled through the air via coughing and 
sneezing, the reasons TB is transmitted to some and not others following 
exposure is not established.32  Also, transmission pathways between 
humans and animals, and vice versa, are not well understood.  Historical 
studies have sought to understand this pathway in ancient populations in 
which evidence of disease was identified in both animal and in human 
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populations, but the transmission from one to another following the 
domestication of animals in prehistoric populations has not been fully 
documented.  More recent history demonstrates a strong relationship 
between human and animal populations.  A study published by Davies 
traces TB reports in nineteenth century slaughterhouses, cow’s milk 
during Victorian times, and possible transmission from cows to humans 
during urbanization through infected milk.  In fact, this transmission 
pathway has been described as an important facilitator of the resurgence 
of disease in the eighteenth and nineteenth centuries held by several 
researchers, proposing that TB infected milk in Great Britain was 
responsible for the epidemic beginning in the Victorian Era through World 
War II.33,34  Further, Davies estimates TB in the food supply remains an 
important risk in developing countries, particularly when food production 
occurs within the bounds of densely populated cities.35  Among the M. 
tuberculosis complex of organisms, M. bovis has been the organism most 
often associated with disease in cattle.  Although few cases of M. bovis 
have been identified through diagnostic methods, some researchers 
suspect this number is underreported given limitations in diagnostic 
techniques in correctly sampling specimens.  Regardless of the potential 
clinical importance of M. bovis, M. tuberculosis remains the most 
important cause of TB infection worldwide.36   
Additionally, some have questioned the animal to human and 
human to animal transmission pattern of other M. tuberculosis complex 
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organisms as well as the role of other animal species.  Several case 
reports are present in the literature of TB having been found in companion 
animals, but the transmission pathway remains unclear.  A case report of 
a nine-year-old pet dog was found to have had tuberculomas in the heart, 
which is a rare manifestation of TB in humans and presumably animals.  
Case reports generally describe the presentation of disease as pulmonary 
or lymphadenopathy.  This report notes that TB infection was not present 
in any members of the household.37  Another case study identified TB 
infection in a companion dog using Polymerase chain reaction (PCR) and 
spoligotyping at necropsy.  This study noted that TB infection was not 
found in household members, but the diseases may have been 
transmitted from the dog to veterinary personnel during necropsy.38  A 
recent case study from Brazil described TB infection and mortality in a pet 
dog following the occurrence of TB in the household.39  Another Brazilian 
case study noted disseminated disease in a 12-year-old pet dog 
diagnosed following the death of one the members of her household 
secondary to pulmonary TB.  The dog in question was noted to have been 
in particularly close contact with the diseased, having been observed 
licking respiratory secretions during his illness.40 
More collaborative and multi-disciplinary research is needed in 
order to better understand the scope of animal to human transmission and 
prevent the transmission of disease through medical and public health 
intervention.  The future of research in this area will depend upon 
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improvements in diagnostic techniques, application of more advanced 
discriminatory genotyping tools, and collaboration with veterinary 
researchers.41 
Further, environmental transmission of TB has not been ruled out 
as a possibility given the presence of pathogenic samples identified in soil 
and water samples.  In a study conducted in metropolitan Tehran, TB was 
identified in 11 of 800 soil samples and 71 of 700 water samples collected.  
Following six months after sampling, 36% of samples from soil and 8.4% 
of samples from water remained culturable.  This finding implies that TB 
organisms remain viable in environmental sources for extended periods of 
time, increasing the possibility of transmitting the disease to human and 
animal populations.42   
Diagnosis 
The process of diagnosing active TB begins with the evaluation of 
symptomology and host factors before proceeding to radiological and 
microbiological findings.  Pulmonary TB has classic symptoms and 
characteristic cavitary lesions usually appearing in the upper lobes of the 
lungs visible on radiological exam.43  However, abnormal host factors can 
undermine classic disease appearance in the lungs.  Host factors also are 
an important indicator of the presentation of extrapulmonary disease.44   
Laboratory findings represent another important factor in disease 
diagnosis.  The diagnosis of TB usually involves a two-step process: 
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smears that determine the presence mycobacterium species and follow up 
cultures or molecular testing that are used for species identification.  
Ideally, a third step in the process should include drug susceptibility 
testing (DST).   
The process begins with smears, which involves staining clinical 
samples in order visualize appearance of the organism.  Characteristic 
features of mycobacterium species are acid-fastness due to the unusual 
thick and lipid cell wall of the organism.  Also, mycobacterium species are 
rod shaped, which would be visualized following smear staining.  A 
number of smear methods are currently used.  Fluorescence microscopy 
represents one of the first and most common laboratory techniques.  This 
method involves the use of flourochrome dyes on the samples along with 
halogen or high-pressure mercury vapor lamps in order to visualize the 
results.  However, the use of fluorescence microscopy relies on reliable 
access to electricity and related infrastructure, which is not realistic in 
some settings.  Conventional smear microscopy using the Ziehl-Neelsen 
technique has been the most common method used in low to middle 
resource countries for this reason.  Although this method has been well 
proven and represents a cost effective smear test in many care settings, 
smear microscopy requires high quality samples.45  Also, the sensitivity 
and specificity decrease when diagnosing extra-pulmonary disease and 
this method is less proven in pediatric populations and in patients with 
compromised immune systems.46,47  
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Because smears only have the capacity to identify mycobacterium, 
follow up tests are necessary for species identification.  Mycobacteria 
cultures can be performed using liquid or solid media.  Liquid cultures 
involve an automated process with a relatively quick turn around time with 
high sensitivity rates.  However, the risk of contamination is higher for 
liquid culture due to the presence of mycobacterium species in water.48  
Polymerase chain reaction (PCR) is an alternative testing method using a 
DNA amplification technique.49  The major advantage of PCR is results 
are reported usually within a couple of days.  High-performance liquid 
chromatography (HPLC) is another molecular method that has been used 
for identifying mycobacterium species.  Having been first introduced in the 
1960s, HPLC has been standard procedure at the CDC Mycobacteriology 
Reference Laboratory since 1990.50,51  Among the major advantages of 
HPLC is that species identification can be as immediate as a few hours.  
However, HPLC relies on high quality specimens and requires highly 
trained laboratory personnel to perform the procedure.  Further, this 
technique is expensive as compared to cultures.  This has important 
implications for use in many low resource, high burden TB countries.  In 
many of these clinical settings, laboratory methodology relies only upon 
smears, and follow up studies involving species identification and drug 
susceptibility testing is not done.52  Also, cultures and molecular testing 
may be done in cases of negative results following smear staining when 
mycobacterial diseases are highly suspected.  All laboratory techniques 
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rely on quality specimens, and have differing capabilities depending on the 
specimen source.  Given that pulmonary infection is the most common 
manifestation of mycobacterial disease, laboratory testing techniques 
generally have a better yield using respiratory samples.  Also, invasive 
collection techniques for respiratory samples such as bronchoscopy are 
considered higher quality specimens.53,54   
The final step that follows smears and species typing is drug 
susceptibility testing (DST).  DST describes the process of testing 
laboratory isolates against common antimicrobial agents in order to 
optimize therapy.  This step is especially important in cases in which 
resistant disease is suspected following the reconciliation of patient 
characteristics that imply a risk for resistant disease.  These factors may 
include a patient history of treatment failure or having been born or visited 
regions of the world in which drug resistance is common.55  Another 
consideration for DST involves the risk of infection from other 
mycobacterium species. 
However, diagnostic challenges persist for many reasons.  First, 
the slow growth of mycobacterium organisms often requires therapy 
initiation in suspected cases prior to official diagnosis.  In some cases, 
patients may be treated improperly for another disease process such as 
community-acquired pneumonia, which represents inappropriate antibiotic 
and healthcare resource use.  Also, the slow development of new 
diagnostic technology remains a persistent challenge.  Given the low 
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prevalence of TB until the end of the twentieth century when global 
resurgence occurred, research and development in TB laboratory 
methodology all but halted along with drug therapies and vaccine studies.  
Only recently has research and development in the area of TB produced 
results that have improved laboratory methods and made available new 
treatment options.  The challenges this creates involve not only 
diagnostics, but also therapy choice.  Slow and difficult microbiological 
testing often results in the initiation of empiric therapies based on the 
clinical suspicion of clinicians in terms of organism and drug susceptibility 
as confirmation of infection may occur weeks later.56,57,58 
Despite the numerous options for laboratory studies, access to 
many of these techniques is unavailable in many care settings.  A recent 
report by UNITAID, an organization developed to address common global 
health concerns in a cost effective approach, is hopeful regarding the 
future of diagnostic technology.  First, the recent introduction of Xpert® 
Mycobacterium TB/Rifampin (MTB/RIF) has been an important 
development that has been encouraging for the future availability of new 
technology.  Xpert MTB/RIF is a new diagnostic technique that replaces 
multi-step process of smears, cultures and susceptibility testing to first line 
drug rifampin is encompassed in one test cartridge.  In 2014, more than 
10 million Xpert MTB/RIF test cartridges were purchased by the public 
sector in 116 of the 145 countries eligible for concessional pricing.  
UNITAID reports that, in addition to Xpert MTB/RIF, a pipeline of 
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molecular diagnostics or nucleic acid amplification tests are in 
development from over 50 companies.  However, the report noted that 
new diagnostic methods will struggle to reach scale.  Also, other 
challenges including long treatment courses persist with no obvious new 
regimens with shorter duration of therapy in the pipeline.  UNITAID also 
emphasized the importance of developing diagnostics that do not rely on 
the availability of sputum samples for select situations, particularly for the 
diagnosis of disease in pediatric populations.  Given that TB 
disproportionately affects low resource countries in greater prevalence, 
UNITAID also raised concerns regarding the availability of new 
technologies to low resource countries specifically.59  Other reports 
examining the future landscape of TB diagnostics have raised similar 
concerns regarding the availability and affordability of TB diagnostic 
technology to the countries in greatest need.60 
Treatment 
Treatment for TB presents a number of important challenges.  
First, anatomical properties of mycobacterium species including an 
abnormal thickness of the cell wall as compared to other bacterial 
organism makes TB resistant to most antibiotics.  This leaves few 
treatment options relative to the several classes of currently available 
antibiotics.  Also, standard treatment for active infection involves a 
regimen ranging from six months to nine months in duration, or four 
months following culture conversion.  During treatment courses, patients 
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must make regular visits to providers to ensure medication compliance as 
well as measure clinical response.  Providers must also prevent 
treatment interruptions or abandonment by ensuring patients maintain the 
ability to be compliant, or transfer treatment in the event of relocation.  
The failure of patients to complete treatment has important implications 
for the continued transmission of disease as well as the facilitation of 
drug resistance.  Another important factor is TB treatment is the 
management of drug therapies relative to adverse reactions and 
comorbid conditions.  Long treatment courses compound the risk of side 
effects and adverse events.  As a result, standard of care involves regular 
blood monitoring in order to identify toxicity and other potentially serious 
side effects.  Also, TB drugs have the potential to interact with treatment 
for several comorbid conditions, which also represents an important 
aspect of medical management.  For these reasons, providers must be 
vigilant in maintaining patient contact during treatment courses.  This can 
be particularly challenging when appropriate treatment requires 
compliance from patient populations known for incompliance.   
Standard treatment for TB may include any of the following first-
line drugs: isoniazid, rifampin, rifabutin, rifapentine, pyrazinamide, or 
ethambutol.  Table 1 outlines the recommended therapy for adults ages 
15 years and older with active infection based on expert guidelines 
published in a joint report by the American Thoracic Society/Centers for 
Disease Control and Prevention/Infectious Diseases Society of 
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America.61    
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For patients with resistance or toxicity to first line agents, TB 
treatment courses may consist of a host of other less effective or less 
proven drug options.  These regimens may be used following a treatment 
failure, resistance reported following DST performed at diagnosis, or 
following a clinical review of medical history that is suspicious for drug 
resistance.  Factors such as recent travel from regions with high 
resistance patterns or medical history with previous regimens and/or 
treatment failures may impact choice in therapy.  Table 2 shows a 
complete grouping of anti-TB therapy.62  
Table 2: Anti-TB Therapy Options 
Group 1: First line (Use all possible drugs) 
Isoniazid Ethambutol 
Rifampin Pyrazinamide 
Group 2: Flouroquinolones (Use only one, agents share genetic targets) 
Levofloxacin Moxifloxacin 
Ofloxacin  
Group 3: Injectable (Use only one, agents share similar genetic targets) 
Capreomycin Amikacin 
Kanamycin Streptomycin 
Group 4: Less effective second line drugs (Use all possible drugs if 
necessary) 
Aminosalcylic acid (acid salt) 
Group 5: Less effective or less proven drugs (Use all necessary drugs 




Amoxicillin with clavulanate Clarithomycin 
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Drug resistance is a common problem affecting the treatment of 
many infectious diseases and is most commonly a consequence of 
overuse and inappropriate use of common drug therapies.  In TB care, 
drug resistance is among the most important challenges, which is a 
worldwide problem affecting both developed and underdeveloped 
countries.  Multi-drug resistant TB (MDR-TB) is characterized by 
resistance to first line drugs isoniazid and rifampin.  Extreme-drug 
resistance TB (XDR-TB) is characterized by resistance to first line drugs 
isoniazid and rifampin, in addition to any fluoroquinolone and one of the 
following three injectable second-line drugs: amikacin, kanamycin, and 
capreomycin.  Scant reports of totally drug resistant TB (TDR-TB) have 
been made in which strains have demonstrated resistance to all drugs 
used for TB treatment.63,64,65 
Drug resistance creates greater challenges in the developing world 
for several reasons.  First, standard laboratory techniques are often limited 
in resource scarce countries, so susceptibility testing may not be standard 
or available.  In these cases, resistance may be diagnosed following a 
treatment failure, which represents more cost to the healthcare system as 
well as a longer treatment course and a greater risk of adverse events.66  
Also, second line therapies may be limited and more costly, which is 
particularly challenging when managing care in underdeveloped countries 
with limited resources.  According to the WHO, 480,000 cases of MDR-TB 
were reported in 2014 worldwide.  An estimated 10% of MDR cases were 
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XDR-TB.  More than half of all resistant cases were in China, India and 
Russia.67   
Epidemiology 
The WHO characterizes TB as a worldwide epidemic with cases 
having been documented in almost every country around the world.  In 
2014, nearly 10 million people developed active disease and 1.5 million 
died as a result.  An estimated one third of the world’s population is 
currently infected, most of which with latent disease.68  Public health policy 
in the US and abroad has focused on treatment and disease surveillance 
of pulmonary TB.  These efforts coupled with improvements in 
diagnostics, treatment, and prevention have reduced the public health 
impact of TB in the US and other western nations.  In the underdeveloped 
world, TB remains an important public health challenge.   
The relationship between TB and poverty is well described.  
Contributing factors driving the transmission of TB is these settings 
include high population density along with malnutrition, concomitant 
medical conditions that affect immunity, and behavioral factors such as 
smoking and alcohol use.  For these reasons, the burden of new cases 
falls disproportionately on poor countries located in Southeast Asia, 
Western Pacific and Africa.  In fact, 80% of new cases occurred in the 
same 22 countries in 2014, including South Africa, Nigeria, India, 
Pakistan, Indonesia and China to name a few.  Also, over 95% of TB 
related deaths occur in low to middle resource countries.69  In many of 
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these countries, HIV/AIDS represents a critical factor predisposing large 
segments of the population to TB infection.  According to some reports, 
HIV/AIDS is believed to be responsible for a three to five times increase in 
the incidence of TB infection in high HIV prevalence countries located in 
sub-Saharan Africa.70,71  TB infection in HIV/AIDS infected hosts often 
presents with more aggressive disease as well as extrapulmonary 
involvement.  In fact, the atypical presentation of TB occurs in more than 
half of patients with advanced HIV/AIDS.  Co-infected hosts also are more 
likely to experience complications as well as medication interactions, and 
TB related mortality in this population is a common outcome.72  A 2014 
WHO report claims that one in three deaths of HIV positive patients can 
be attributed to TB, emphasizing the particularly devastating role HIV 
plays in TB in countries with high HIV/AIDS prevalence.  The WHO also 
reports that HIV infected patients are 20 to 30 times more likely to 
progress to active disease from latency as compared to the general 
population.73  The impact of HIV/AIDS is easily illustrated in the figure 
below outlining a comparison of worldwide TB incidence showing data 
from high-income countries verses other world regions including a 
stratification of data from Africa separately reported based on high 




Figure 1: Global TB incidence 1990-2008 
The availability of current diagnostic methods and anti-TB therapies 
has been one of the most important developments in addressing TB as a 
worldwide global health concern.  An estimated 43 million lives were 
saved between the years 2000 and 2014 as a result of TB diagnostics and 
treatment.75   
Nontuberculous mycobacteria  
Nontuberculous Mycobacterium (NTM) describes a group of 
organisms ubiquitous to the environment that have been associated with 
disease in both humans and animals.  Recent reports indicate that NTM is 
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an emerging pathogen in many parts of the world, but particularly in 
developed countries in North America, Europe, Asia and Australia.76  In 
the US, NTM rates are sharply rising in prevalence, particularly in the 
older population of adults.77,78  NTM is a source of significant morbidity in 
the US.  Patients with NTM infection require extensive healthcare 
resources including hospitalizations, frequent outpatient visits, and 
complicated therapy with associated treatment challenges.  NTM is also 
an increasingly important cause of mortality in the US.79,80,81 
History 
NTM was first identified in the 1950s by Ernest Runyon.  A botanist 
who published his findings in 1959, Runyon categorized the newly 
discovered species based on growth rates, colony morphology, and 
pigmentation.82  Prior to Runyon’s discovery, the history of NTM as a 
human pathogen remains unknown. 
The Runyon system categorizes NTM species into 2 primary 
categories: slow growing and fast growing.  Slow growing NTM are further 
organized into three subcategories based on the pigment production.83   
The contemporary Runyon classification system consists of a considerably 
higher number of NTM species as more continue to be discovered.  
Currently, more than 150 species of NTM have been identified.84,85  As 
advances in laboratory methods have evolved in recent years, the Runyon 
classification system based on growth rates and pigment production has 
become less relevant.  New rapid culturing techniques including DNA 
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probes and high-pressure liquid chromatography do not abide by the 
Runyon classification system.  Also, the Runyon classification does not 
reflect unique clinical features of each pathogenic NTM species.86,87  
Table 3: Runyon Classification of NTM Species  
Slow Growers (Colonies may take 
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Despite recent advances in NTM research, this field of 
mycobacteria remains understudied.  A lack of support in the form of 
international grants as suggested by one study is responsible for the 
deficit in clinical and basic science research in the area of NTM.65  In the 
US, only 5 of the 228 grants available from the National Institute of Health 
(NIH) include sponsorship for research in NTM.88  Therefore, the field of 
NTM research represents an important unmet need relative to the rising 




The majority of NTM cases manifest in the form of pulmonary 
disease, as is the case with TB infection.  Extrapulmonary NTM, or NTM 
cases that present in the form of infection outside of lung disease, is 
estimated to occur in the US in up to 10% of cases.89  NTM infections 
have the potential to involve any site in the human body.  Atypical 
presentations cause a number of infections including lymphadenitis, septic 
arthritis, osteomyelitis, skin and soft tissue infections, and disseminated 
disease.90,91,92  
NTM disease can be caused by a number of different species as 
many are considered pathogenic to humans.  Currently, more than 150 
species of NTM have been described, with new ones being routinely 
discovered.9  The most common NTM pathogens associated with human 
infection are the species associated with Mycobacterium avium complex 
(MAC).  MAC describes infections caused by two primary organisms, M. 
avium and M. intracellulare, as well as any one their genetically similar 
subspecies.  In the US, MAC accounts for up to 80% of pulmonary NTM 
infections according to some reports.93,94,95  Other reports classify more 
than half of NTM cases in the US as MAC, and global figures are only 
slightly less.  Molecular sequence data have identified 10 subspecies of 





Table 4: MAC Subspecies Organisms 
Mycobacterium Avium Complex Subspecies Organisms 
M. avium M. intracellulare 
M. homisissuis M. bouchedurhonense 
M. silvaticum M. timonense 
M. paratuberculosis M. arosiense 
M. colombiense M. marseillense 
Although MAC represents one of the most important causes of 
NTM disease, many NTM species have been associated with human 
diseases.  See Table 5 for a listing of common NTM pathogens that have 
been strongly associated with infection in humans.97 
Table 5: Common NTM Human Pathogens  
Common NTM Human Pathogens 
M. avium complex (MAC) M. porcinum 
M. kansasii M. conceptionense 
M. porcinum M. phlei 
M. lentiflavum M. austroafricanum 
M. monacense M. elephantis 
M. abscessus M. parascrofulaceum 
M. thermoresistibile  
According to a recent study outlining the epidemiology of NTM 
species as a cause of pulmonary disease, the geographical variation of 
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NTM varies considerably between sample data from six continents.  
Overall, MAC still represents the most common cause of pulmonary 
infection.  See the figures below for a representation of the most common 
NTM species associated with disease in humans based on global 
averages as well as figures for North America.  These data demonstrate 
both the clinical importance of MAC on both a global scale and in North 
America, as well as the other NTM pathogens as important causes of 
disease.  Also, these data emphasize the importance of rapidly growing 
mycobacteria (RGM) as a cause of disease in North America.98  The most 
common RGM species are M. fortuitum, M. abscessus, and M chelonae.99 
 
 











Figure 3: NTM Species as a cause of disease in North America 
The amount of NTM to which one has been exposed has also been 
shown to predict the likelihood of disease.  However, the infectious dose 
for NTM infection remains unknown but current estimates demonstrate 
this at anywhere between 10-102 units.100  In a mouse model, M. ulcerans 
infections identifiable by swelling occurred following exposure to a dose of 
103-104 colony-forming units.101  This relationship has not been tested in 
other NTM species and hosts, including humans. 
As is the case with TB infection, host factors play a critical role in 
susceptibility and clinical features of NTM infections.  NTM is generally 
considered opportunistic pathogens, which means that some level of 
immunodeficiency or preexistent pulmonary disease usually exists in 
patients with NTM.102  Four categories of well-defined susceptibility for 
NTM infection have been identified.103  First, structural or preexisting 










pulmonary diseases such as cystic fibrosis, chronic obstructive pulmonary 
disease (COPD), and bronchiectasis have been strongly associated with 
the risk of developing many types of infectious lung diseases including 
NTM.104  Second, patients with autoimmune disorders who are being 
treated with antitumor necrosis factor-α (TNF-α) drugs are at risk for 
developing NTM as well as many other opportunistic infections.  Third, 
HIV infected persons with AIDS are also at an increased risk for 
developing NTM along with many other opportunistic infections.  In fact, a 
CD4+ T cell count of less than 50 cells/µL is associated with increased 
risk of disseminated NTM disease.  Fourth, patients with genetic 
syndromes involving mutations in the interleukin-12 or interferon γ 
pathways are also at risk for developing opportunistic infections including 
NTM.  Mutations in these pathways are associated with both autoimmune 
disorders as well as immune suppression.105,106,107,108 
In addition to these defined risk groups, solid organ transplant 
recipients also have increased risk of NTM disease for several reasons.  
Post-transplantation immunosuppressive therapy increases the likelihood 
of clinical disease from environmental exposures.109  Also, underlying lung 
disease in lung transplant patients place patients at a higher risk for NTM 
infection during the pre-transplant period.  Possible risk factors for the 
recurrence of infection or the onset of new disease with NTM following 
lung transplantation are immunosuppression and the development of 




The risk of developing NTM is also strongly associated with 
advanced age and the presence of comorbidities.  This is believed to 
contribute to the recent increase in cases in the US given the aging of the 
population in the US, Canada and parts of Europe.112,113  Additionally, 
nonsmoker elderly females with a slender body along with characteristic 
features such as scoliosis, pectus defects, or mitral valve prolapse are 
more prone to pulmonary NTM as compared to the general 
population.114,115,116  In fact, NTM occurring in this population has been 
termed Lady Windermere syndrome, and has a characteristic presentation 
in the right middle lobe and/or lingua.  Lady Windermere syndrome is 
believed to be associated with voluntary cough suppression that causes 
secretion accumulation creating an ideal place for growth of the NTM 
organisms.117  Also, the elderly are more likely to be complicated to treat 
given their increased likelihood to have comorbidities.     
NTM infection is also more common in patients with specific 
behavioral risk factors such as tobacco use, alcohol use and poor 
nutrition.118  Despite well-defined risk groups, patients present with NTM 
infection without obvious risk factors or the present of underlying 
disease.119   
Perhaps the most important host characteristic associated with 
NTM infection is HIV/AIDS.  Given that HIV is still commonly diagnosed in 
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the US during late stages of the disease, the presentation of NTM in an 
atypical host sometimes leads to an HIV/AIDS diagnosis.120  In fact, the 
presence of NTM is considered by many experts to be an AIDS defining 
illness, which is characterized by the presence of less than 200 CD4 T-
cells that is often discovered following the diagnosis of opportunistic 
infections, which often includes NTM infection.121   
HIV/AIDS represents one of the most important risk factors for NTM 
disease in patients of all ages including older populations.  According to 
the CDC, people aged 55 and older accounted for an estimated 24% of 
the 1.2 million people living with HIV infection in the US in 2012.  
The prevalence of HIV/AIDS in older populations can be attributed 
to several factors.  First, the effectiveness of HAART (Highly Active Anti-
Retroviral Therapy) in extending life spans of those infected with the virus 
early during the HIV/AIDS epidemic have allowed HIV patients to age.123  
HAART has extended lifespans well beyond expectation allowing many to 
age into retirement with a disease that was once considered a death 
sentence.  The majority of this population is made up of the more 
traditional at risk population of HIV positive adults including those who 
acquired the disease through homosexual contact and IV drug use.   
Newly diagnosed cases within this same age cohort have also 
increased in recent years.  An estimated 27% of patients over 50 years of 
age accounted for new diagnoses of AIDS in 2013.  The diagnosis of 
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AIDS usually follows the identification of AIDS defining opportunistic 
infections, which often includes a diagnosis of NTM disease.  In older 
populations, the CDC notes that late diagnoses are more common as 
compared to younger populations.124  Among the unique risk factors for 
this age group is a statistically significant increase of transmission through 
heterosexual contact, which has specifically impacted the incidence of 
HIV/AIDS in females over the age of 50.  Given the low perceived risk of 
heterosexual contact in this population, older adults are less likely to take 
HIV/AIDS prevention measures.125  The CDC notes that clinicians treating 
this population are less likely to suspect HIV/AIDS despite the presence of 
clinical symptomology and older patients are less willing to share with their 
care providers HIV/AIDS risk behaviors.126  Another important factor in the 
prevalence of disease in the older populations is the estimated 80% 
increase in erectile dysfunction treatment prescriptions in recent 
years.127,128   
Another important factor is HIV/AIDS transmission in older 
populations, some scholars suggest that the aged are more likely to 
seroconvert than their younger counterparts if exposed to the disease.  
Among the explanations for this, age-related hormone production levels 
decrease in the aged, resulting in the thinning of the vaginal and anal 
mucosa.  As a result, the likelihood of tearing during sexual contact 
increases which allows a point of entry for the virus.  Also, age-related 
immunity function declines which leaves older adults more vulnerable to 
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infection if exposed.129   
Transmission 
NTM species are environmentally ubiquitous organisms and 
disease transmission is believed to occur primarily from the environment.  
Having been isolated in various studies in soil and water sources, 
understanding the factors contributing to the transmission of disease to 
some hosts and not others remains an area of study.  Emerging research 
has demonstrated that NTM can be transmitted person to person.  Also, 
the relationship between humans and animals, and vice versa, is an 
important area of future research.  Finally, the food supply, primarily fish 
living in water contaminated with NTM is another possible source of 
transmission.   
Reports from different parts of the world have identified various 
species of NTM in environmental sources, including soil, dirt, household 
water supplies, public water supplies, workplaces, and hospitals.130,131  In 
a review surveying data from several Middle Eastern countries, NTM was 
found in 619 environmental samples collected in Iran, Iraq, Turkey and 
Saudi Arabia and the most common species noted in these isolates was 
M. fortuitum.132  Several studies have also identified the presence of NTM 
in soil and water samples.  Soil samples collected from a forest located in 
Finland identified the presence of NTM in 100% of the 47 samples.133  A 
Japanese study tested a variety of environmental samples and found the 
presence of NTM in 100% of 5 dirt samples, 100% of ditch mud samples, 
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77% of 22 house dust samples, and one of two river water samples.134  
Water as a source of environmental NTM is well described in a 
variety of studies collected from several different water sources.  An 
analysis of brook water collected from sources in rural Finland found that 
NTM was present in 100% of 53 samples.135  In an Australian study, the 
presence of MAC was identified by PCR in two water distribution 
pipelines.  Later sampling during the summer months noted that the 
concentration of the organism significantly increased, which implies the 
organism multiplied while in the pipeline and became more infectious.136  
In a study evaluating patients with MAC, NTM was identified in the home 
water samples from 10 patients.137   
In a 2013 doctoral dissertation, the relationship between NTM 
isolated from a municipal water source and human infection was 
evaluated.  In this study, water samples were taken from the municipal 
water supply in Queensland, Australia and compared with clinical samples 
collected from the same area.  NTM was isolated in more than 40% of 
water samples during summer months and 82% of samples collected 
during winter months.  The NTM species discovered included both species 
that are considered pathogenic to humans as well as nonpathogenic NTM.  
M. abscessus was not identified in water samples collected in this study.  
It is important to note that this particular NTM species is rarely isolated in 
water, as opposed to M. kansassi, which is so strongly associated with 
water, it has been termed the “tap water bacillus.”  Further investigation 
 38 
 
was conducted in the homes of 20 patients with a diagnosis of NTM in 
which samples collected from showerheads were compared.  A total of 7 
(35%) patients were diagnosed with the same species of NTM that was 
identified in the showerheads of their home.  This study also compared 
nosocomial, or hospital acquired, and community associated infections 
caused by M. fortuitum to the samples identified in the municipal water 
samples through strain analysis.  Similarities were founds which implies 
contamination within the hospital water supply.  Strain similarities were not 
found in community associated infections caused by M. fortuitum, 
indicating that water was likely not the mode of transmission in these 
cases.138  See below for comparison data of NTM species identified in this 
study in water samples and clinical isolates. 
Table 6: Pathogens Collected from Water and Clinical Samples 
Pathogens Identified in Water Pathogens Collected 
from Clinical Isolates 
M. gordonae M. lentiflavum  M. lentiflavum 
M. szulgai M. fortuitum M. fortuitum 
M. simiae M. kansasii M. kansasii 
M. terrae M. flavescens M. abscessus 
M. chelonae M. interjectum  	  
M. intracellulare M. mucogenicum  	  
M. avium complex   	  
Water from home and public water sources has been evaluated.  In 
a study of 31 patients from the US and Canada with NTM disease due to 
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MAC, M. abscessus, and M. xenopi, the species identified in the patient 
was also isolated in their home in 46% of cases.139  In a Saudi study, NTM 
was isolated from the mouthwash of 44 (26.3%) subjects that used tap 
water versus 10 (33%) subjects that used sterile water.140  In a review, the 
authors emphasized the importance of intentionally designing engineered 
water systems based on quantitative microbial risk assessment.  This 
recommendation came following a discussion of numerous studies 
isolating NTM, legionellae and Pseudomonas aeruginosa from public 
water sources.141  Also, research has evaluated the possibility of 
transmission through aerosolized water.  Theoretical sources of 
aerosolized NTM include primarily showerheads and hot tubs.  A study 
examining household water and showerheads of patients with NTM 
pulmonary disease identified matched environmental and human strains of 
M. abscessus, M. lentiflavum, and M. kansasii in 20 patients142  In a study 
evaluating 18 public hot tubs and warm water therapy pools, the presence 
of NTM in was found in 13 sites (72%).  Proper water care using chlorine 
or bromine sanitation significantly lowered the concentration of NTM 
identified in this study.143   
NTM infection from food sources is another possible mode of 
transmission for which few data exist.  One recent study suggests that 
NTM might be transmitted from freshwater fish and fish products following 
the review of 92 tissue samples obtained from ponds, retail fresh, frozen 
fish and smoked fish products.  In this study, nearly 12% of samples 
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evaluated tested positive for pathogenic NTM.144 
Although NTM was previously believed to only be transmitted from 
environmental sources, emerging data suggests that human-to-human 
transmission occurs in patients with cystic fibrosis.  A 2011 report in which 
168 isolates collected from 31 cystic fibrosis patients with NTM infection 
due to M. abscessus was tested using whole genome sequencing and 
drug susceptibility testing revealed the frequent transmission of multidrug 
resistant NTM between patients.145  
Despite these reports, the transmission patterns of NTM are not 
well described.  Transmission from environmental sources seems to occur 
from a myriad of soil and water sources that surrounds communities, and, 
in some cases, lives in our homes while emerging data indicate that NTM 
may even be transmitted from food sources.  The factors influencing the 
transmission of disease from environmental pathogens remain 
unknown.146  Further, the transmission of NTM disease from animals to 
human, humans to animals and humans to humans is a critical area of 
future research.  Improving the understanding of transmission pathways is 
critical to crafting a more effective response to this emerging public health 
problem.   
Diagnosis 
The diagnosis of NTM infection involves the correlation of clinical 
signs and symptoms with radiological and microbiological findings.  Given 
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its similar appearance to TB, NTM diagnostics can be especially 
challenging as the two diseases may appear identical in disease 
presentation.  Also like TB, the diagnostic process consists of several 
important components and multiple layers.   
The microbiological studies process begins with a smear stain, 
which determines whether the specimen is a mycobacterium species.  
Common smear staining techniques include fluorescence microscopy and 
Ziehl-Neelsen.  Given the differing sensitivity and specificity of these 
staining procedures for various mycobacterium species, a combination of 
smear techniques may be used.147  Once the specimens are determined 
to be acid fast bacilli, specimens are prepared for isolation.  The first step 
in this process involves the use of N-acetyl-L-cysteine-sodium hydroxide 
(NALC/NaOH), which serves as a decontaminant that prevents the growth 
of other bacteria.148   
When smears are followed by cultures, the positive identification of 
NTM depends of the growth rate of the organism.  Most NTM strains grow 
within two to three weeks with the exception of rapidly growing 
mycobacteria species M. abscessus, M. fortuitum, M. chelonae, and M. 
massiliense, which may grow within 7 days.149   
Recently developed methods may also be used for a quicker result.  
High-performance liquid chromatography (HPLC) is a molecular method 
that involves the use of species specific probes.150  HPLC recognizes 
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mycobacteria according to variations in mycolic acids, the long-chain fatty 
acids resided in the cell wall of mycobacteria.151  The major advantage of 
HPLC is rapid species identification.152  However, molecular DNA probes 
are available for identifying a select few NTM species including MAC, M. 
gordonae, and M. kansasii.  Therefore, NTM infection due to other causes 
is not diagnosable using this method.  The HPLC method is also more 
costly, requires reliable laboratory infrastructure and well trained 
technicians to carry out the test, which may limit its availability in some 
care settings.153,154  PCR restriction fragment length polymorphism 
analysis is another molecular technique for identifying mycobacteria on 
account of differences in restriction fragments of the 65 kD heat-shock 
protein.  Sequence analysis of the rpoB gene and 16S ribosomal RNA has 
been expanded recently as another method for speciation of NTM.155,156 
Significant improvements in the laboratory methods that identify the 
presence of mycobacteria have occurred over the last two decades.  Also, 
species identification has allowed the opportunity to further expand the 
clinical and epidemiologic database regarding NTM.157  Despite recent 
advances, diagnostics remains challenging for several reasons.  First, due 
to the ubiquitous presence of NTM species in the environment, the 
likelihood of contamination is high and can occur before, during or after 
clinical samples are collected.  Many possible scenarios exist for 
contamination.  For example, sputum samples may be contaminated when 
traveling through the mouth during collection.158  Following arrival to the 
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laboratory, samples may be contaminated by equipment.  The 
contamination of a fibrotic bronchoscope suction channel has been 
reported as the cause of several positive cultures for M. chelonae.159  
Given that many mycobacterium species live in water, it has been 
reported that liquids used during the culture process exist as another 
possible source of contamination.160  For these reasons, the reliance on 
microbiological findings must be carefully considered alongside clinical 
and radiological. 161,162  
The diagnosis of NTM disease is defined by the positive 
identification of a pathogenic NTM species in a clinical isolate in addition 
to clinical signs and symptoms of disease.  In a statement published by 
the American Thoracic Society/ Infectious Diseases Society of America 
(ATS/IDSA) is the official definition of pulmonary NTM as outlined in the 
table below.164  
Table 7: ATS/IDSA Official Definition of pulmonary NTM  
 ATS/IDSA Criteria for pulmonary NTM  
1 Chest radiograph showing opacities, nodular or cavitary, or a high-
resolution computed tomography (HRCT) scan that shows multifocal 
bronchiectasis with multiple small nodules; and 
2 Three or more sputum specimens positive for acid-fast bacilli (AFB); 
and 
3 The exclusion of other causes including TB. 
The panel of experts emphasized that these criteria were designed 
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for the unique infectious processes of MAC, M. kansasii, and M. 
abscessus, noting that ATS/IDSA criteria cannot be applied to other 
species of NTM because there is not enough data to confirm a similar 
infectious process for all species of NTM. 165 
Following the diagnosis of NTM infection and the identification of 
NTM species, the next critical step in NTM infection management is DST.  
For NTM, laboratory isolates are tested against common antimicrobial 
agents in order to optimize therapy.  This is particularly important because 
most NTM strains are usually resistant to agents used to treat TB, leaving 
fewer options for treatment as compared to many other diseases.  Also, 
many preferred agents such as clarithromycin may not be effective in 
some strains.167  Current ATS/IDSA guidelines recommend drug 
susceptibility tests for MAC against macrolide antibiotic class, M. kansasii 
against rifampin, and rapid growing mycobacteria against various 
antibiotic classes including newer macrolides and quinolones, doxycycline 
and minocycline, and sulfonamides.168  
Treatment 
The treatment of NTM is long-term and complex consisting of 
bacteriologic surveillance, monitoring for drug toxicity, and managing 
comorbidities.  Also, with the absence of randomized clinical trials 
published in peer-reviewed literature, current guidelines for treatment are 
based largely on expert opinion using what little data are available.  
Guidelines vary depending on site of infection, host characteristics, and 
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NTM species.  Therapy duration is also highly variable, dependent largely 
on repetitive negative cultures for a period of time, usually one year.  
Given these long treatment courses, monitoring and managing the 
sometimes harmful side effects associated with long-term antibiotic use is 
an important component of NTM management.  Further, because NTM 
patients tend to have underlying diseases coupled with advanced age, 
treatment can be complicated with providers having to manage drug 
therapy and side effects alongside comorbid conditions and associated 
therapy.  Finally, all of this requires strong patient compliance over a long 
treatment course.  
An example of NTM therapy as recommended by the ATS/IDSA for 
NTM species MAC for patients who are not HIV positive with pulmonary 
infection may include clarithromycin (1000 mg three times per week) or 
azithromycin (500 mg three times per week); and rifampin (600 mg three 
times per week) or rifabutin (300 mg three times per week); and 
ethambutol (25 mg/kg three times per week).  For patients with 
fibrocavitary MAC lung disease or severe nodular or bronchiectatic 
disease, the ATS/IDSA guidelines recommend clarithromycin (500 to 1000 
mg daily) or azithromycin (250 mg daily); and rifampin (600 mg daily) or 
rifabutin (150 to 300 mg daily); and ethambutol (15 mg/kg daily).  In some 
cases, streptomycin or amikacin (both 10 to 15 mg/kg three times per 
week) may be added as a fourth agent for the first eight weeks.  A lower 
dose (6 to 8 mg/kg two to three times weekly) may be appropriate for 
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patients who are older than 50 years of age, whose weight is <50 kg, or 
who require parenteral therapy for longer than two to three months.  For 
the same patient population with M. kansasii, the second most common 
NTM organism, ATS guidelines recommend combination therapy 
consisting of isoniazid (300 mg daily), rifampin (600 mg daily), ethambutol 
(15 mg/kg per day) in the same patient population.  Therapy duration is 
generally one year following the first negative culture result assuming 
subsequent results are also negative.169  
The presence of comorbid conditions also contributes to potential 
treatment complications for NTM disease.  As many older Americans 
maintain regimens of maintenance medications, prolonged concurrent 
therapy can present clinicians with many treatment challenges.  For this 
reason, NTM treatment must be chosen carefully in order to avoid drug-
drug interactions with existing and necessary concurrent medication.  
Antibiotic classes commonly used to treat NTM cause interaction with 
drugs that interact with cytochrome P-450 (CYP), which includes  drugs 
commonly used to treat a myriad of disorders including anxiety, psychiatric 
disorders, seizure disorders, hyperlipidemia, hypertriglyceridemia, atrial 
fibrillation, and bleeding disorders.170  In other patient populations such as 
patients that are HIV positive, patients with extra pulmonary infection sites 
or disseminated disease, or patients with documented resistance following 
DST or previous treatment failures, other recommendations using less 
proven treatment regimens may be used. 
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In select cases of NTM infection, surgical resection may be a 
consideration.  Indications for surgery have not been uniformly defined, 
but are most commonly associated with medication intolerance, drug 
resistance, localized cavitation, recurrent or massive hemoptysis, and the 
presence of a destroyed lung.  The safety of lung resection for NTM lung 
disease, particularly thoracoscopic right middle lobe lobectomy and 
lingulectomy, has been reported as favorable in carefully selected patient 
populations and under the care of experienced surgeons.  Data have 
shown that surgery provides improved microbiologic response for 
refractory organisms such as M. abscessus as compared to medication 
regimens alone.171,172,173 
Epidemiology 
Infections caused by NTM are an increasingly important cause of 
morbidity and mortality.  Infection is the result of the interaction between 
exposure load and host characteristics including underlying diseases, age, 
behaviors, and genetic predispositions.  Virtually everyone is routinely 
exposed to NTM, although most do not develop clinical signs of infection.  
The factors predisposing one to infection are not well understood.174  
United States population-based data indicate that the number of deaths 
from NTM disease is growing.  During the years 1999 through 2010, NTM 
disease was reported as an immediate cause of death in 2,990 people in 
the United States with a combined overall mean age-adjusted mortality 
rate of 0.1 per 100,000 person/years.  Persons aged 55 years and older, 
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women, those living in Hawaii and Louisiana, and those of non-Hispanic, 
white ethnicity had higher mortality rates.  In fact, some evidence suggests 
that NTM is a more common cause of death in the US than TB.175  The 
majority of NTM deaths were reported in the hospital setting.176  
Additionally, there is a strong association between age and NTM mortality, 
which was found to be significantly higher in patients older than 65 years.  
In addition to the presence of comorbidities common in this population, 
advanced age itself was determined to be a strong predictor of 
mortality.177,178  Morbidity can also be significant for patients with NTM 
infection.  A national cohort study found that respiratory failure is more 
common in patients with NTM after adjusting for potential confounders 
such as age and the presence of comorbidities.179 
The epidemiology of NTM is vastly different from TB, and has 
changed significantly in recent years.  First, NTM is becoming increasingly 
common in wealthy industrialized countries, while respective TB rates are 
on the decline.180  However, NTM is a non-reportable disease in the US 
and its epidemiology is not well described in the literature or by other 
sources of disease surveillance, resulting in infection rates being difficult 
to piece together.  The prevalence of disease in North America was 
reported at 1.6-1.8 per 100,000 in the 1980s whereas recent reports 
record a prevalence of 14.1 per 100,000.181  Current reports indicate that 
NTM exceeds TB infection rates in the USA according to data from 
Oregon found the total age-adjusted prevalence of NTM was reported at 
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8.6 per 100,000 cases in the 2005-2006.  This number increased to 20.4 
per 100,000 in adults 50 years of age and older.  The median age was 66 
years and 59% were females.182  In a combined report of four other 
regions in 2010, the mean annual prevalence was 5.5 per 100,000, 
ranging from 1.7 per 100,000 in Southern Colorado to 6.7 per 100,000 in 
Southern California.183  According to findings from a national Medicare 
claims data study, the annual prevalence of NTM in the population older 
than 65 years old significantly increased from 20 cases per 100,000 
persons in 1997 to 47 cases per 100,000 persons in 2007.  The study also 
found interesting demographic features, including that Caucasians 
accounted for 90% of cases followed by Asians/Pacific Islanders and 
African-Americans.184,185   
A number of explanations exist for these trends.  First, North 
America and Europe demonstrate a dramatic decline in TB rates given 
successful public health interventions coupled with the development of 
anti-TB medication over the last century.  Also, the recognition of NTM 
along with the ongoing identification of more NTM species have allowed 
clinicians to improve diagnostic methods so that NTM cases are not 
misdiagnosed and treated as TB.  Some of this technology is not available 
or affordable in developing countries, resulting in NTM not only being 
misdiagnosed and treated, but also facilitating resistance to anti-TB drugs 
characterizing MDR and XDR-TB.  Another important contributor to the 
rise in NTM infection in North America and Europe is a population aging.  
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Environmental factors are also important as warm and humid climates 
have been associated with higher rates of infection. 
The population composition of North America and many parts of 
Europe demonstrate population aging coupled with overall population 
shrinking. In the US, population composition is uniquely impacted by the 
baby boomer generational cohort.  The baby boom is characterized by the 
post World War II bump in birth rates that began in the middle of 1946 and 
continued into 1960.  This noticeable increase in births exists alongside a 
decline in births during subsequent years, resulting in the baby boomers 
commanding a significant proportion of the population.  In 2010, the 
elderly in the US was estimated to be approximately 40.2 million.  Given 
that baby boomers are just now entering retirement, the number of elderly 
Americans is expected to grow in coming decades.  Further, population 
composition projections demonstrate this trend will remain as the baby 
boomer cohort enters the very elderly years.186  Projections from the US 
Census Bureau show population structure challenges associated with the 
baby boomer generational cohort marks only the beginning of elderly 
Americans making up a significant proportion of the population.187  As the 
generation after the baby boomers enters retirement years, the number of 
elderly Americans is expected to increase to 88.5 million by 2050.188  See 
the figures below for projections from the US Census Bureau that 
demonstrate the impact of the baby boomer generational cohort relative to 




Figure 4: US population by age and sex in 2012 and projections  
Given that many entitlement programs in the developed world are 
in place relying on the support of younger citizens, population aging and 
shrinking has resulted in deficits and shortfalls.  In the US, the future of 
Medicare and social security have been an important political debate for 
several election cycles as policy makers have expressed concern with 
funding these programs in the future using conventional methods.  Also, 
the high utilization of healthcare resources by the aging population has 
also been an important cost driver for healthcare in the US that is only 
expected to worsen as the baby boomers continue to age.  Therefore, 
population aging has had many important implications for the funding of 
public programs as well as managing the cost of many illnesses 




NTM prevalence differs by geographic region due to specific 
environmental factors linked to climate, water, and soil exposure.  Given 
the most common sources of NTM species are water and soil, swampy, 
humid southeastern states in the US have more cases of disease than the 
dry west or the cold north.  A report of pulmonary NTM identified 55 
counties in 8 states with a particularly high risk of infection, which included 
parts of California, New York, Florida, Hawaii, Louisiana, Oklahoma, 
Wisconsin, and Pennsylvania. A map of state reported variations in NTM 
infection are illustrated blow.193 
Figure 5: NTM rates by state in the US 
NTM is an important infectious disease that represents a new 
public health challenge.  Given its similarity to TB both in both 
presentation and microbiology, NTM was only recently recognized as a 
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human pathogen.194,195  Diseases caused by NTM generally have 
prolonged treatment in order to achieve a complete cure.  Therefore the 
prevalence is far greater than the incidence.  While efforts in treatment 
and surveillance of TB have resulted in a decrease in the incidence in 
recent years, the incidence of NTM is increasing which has classified NTM 
as an emerging public health problem in the US and the world. 196,197,198  In 
a national cohort study, populations underwent screening for the NTM 
species M. intracellulare during the years 1971–1972 and 1999–2000.  In 
the earlier cohort, a total of 1,490 participants were evaluated and 7,384 
were included in the later cohort.  This study found that one in nine 
participants in the 1970s tested positive as compared to one in six in 1999 
and 2000.  The authors conclude these findings are consistent with the 
overall rising rates of NTM in the US.199  According to a study conducted 
in Oregon, NTM rates were in excess of TB in the population sampled.  
Given that Oregon has TB rates comparable to fourteen other states as 
well as demographic similarities with thirty-five other states, the authors 
suggest that NTM is likely more prevalent than TB in several states in the 
US.200  
Recent surveillance data was presented at the 2016 IDSA meeting 
in New Orleans, LA.  In this study, data was retrieved from the National 
Center for Health Statistics between the years 1999 and 2014 for cases in 
which NTM was noted as a contributing or underlying cause of death.  
This database includes causes of death as recorded on death certificates 
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along with demographic data of the deceased from all fifty states in the 
US.  Demographic data was collected including age, race, gender and 
comorbid conditions.  This study established the mortality burden of NTM 
at 2.3 per 1,000,000 persons over the past 15 years.  This study also 
confirmed established demographic features of the disease, noting that 
mortality was significantly higher among older white women.  Also, 
comorbid conditions most strongly associated with mortality were 
structural lung diseases such as cystic fibrosis, bronchiectasis and 
pneumoconiosis.  Further, this study found that HIV status was the only 
non-pulmonary comorbidity that was found to be a predictor of mortality; 
however, data from this study noted that HIV co-infection rates in patients 
dying with NTM infection declined during the fifteen year study period as 
NTM rates in patients without HIV infection has increased.  The purpose of 
this study was to provide national surveillance data for NTM mortality rates 











CHAPTER 2: STATEMENT OF THE PROBLEM 
AND LITERATURE REVIEW 
Mycobacterial infections are a source of significant economic 
burden in the US and the world.  The cost burden of TB and NTM are 
multifaceted, including complex direct medical costs which include not 
only managing the infection and related therapies and procedures, but 
also minimizing the impact of common side effects, identifying and 
preventing potentially dangerous adverse reactions, managing comorbid 
conditions as they relate to therapy, and minimizing the cost of treatment 
failures and other therapy challenges.  Given that health care costs have 
been key factors in national economies worldwide, controlling health care 
costs has become a priority for essentially all countries in the world, and is 
an important area of research.   
Mycobacterium tuberculosis 
Mycobacterium tuberculosis (TB) represents a worldwide public 
health challenge with corresponding cost implications.  In the developed 
world, TB was once a nearly eradicated disease that has resurfaced 
secondary a number of factors.  Among these are immune suppression as 
a result to the HIV/AIDS epidemic, diabetes mellitus, or immune 
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suppression therapies, immigration, and the development of drug 
resistance.202  In the underdeveloped world, TB has emerged with an 
often disproportionately high rate of HIV/AIDS, malnutrition and other 
poverty related causes of immune suppression, coupled with resource 
constrained health care delivery systems.  In many of these countries, 
national TB programs have been established to deliver TB related 
treatment at no direct cost to the patient.  However, the reality of many TB 
programs in resource-constrained countries is characterized by a failure of  
to meet public demand, limited access to drug therapies, and a reliance on 
outdated or incomplete laboratory methods.  Also, indirect costs 
associated with TB disease such as food and travel can result in further 
impoverishment for the very poor.  This situation is often exacerbated by 
the loss of wages secondary to the disease process and the time 
investment necessary to seek treatment.  In these cases, adding the cost 
of direct medical care can be potentially devastating to many vulnerable 
populations.203        
TB in the Underdeveloped World 
The prevalence of TB is disproportionately high in developing 
countries located primarily in Asia and Africa.  Given the strong 
association between TB and poverty, the risk of driving vulnerable 
populations into further poverty as a result of TB infection is important with 
significant implications for long-term quality of life.  Several studies have 
examined cost as a means of measuring the impact of TB on individuals 
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and their families as well as in the context of national resource planning.  
In the current body of medical literature, the financial burden of TB has 
been measured from a variety of perspectives.  Also, cost data are widely 
available in the context of national and international policy, resource 
planning, technology assessment as well as the measurement direct and 
indirect treatment cost relevant to patients and their families.  The 
conclusion of the majority of these studies is not encouraging, noting that 
TB can be particularly devastating for patients, their families and/or 
caregivers, as well as threatens the fragile healthcare delivery systems in 
resource scarce countries.  
Program Delivery Costs 
The TB delivery system in most countries is complex resulting in 
many challenges in measuring cost.  For example, in countries that 
theoretically provide TB care at no direct cost to the patient, free services 
may not be available due to resource constraints, may not be offered to 
patients due to unavailability or corruption, or indirect expenses or lost 
wages may not be offset with vouchers or other expense reimbursement 
and wage replacement programs.  Only one of these factors being present 
within many populations can be financially devastating.   
The financial impact of TB disease is heterogeneous in the 
developing world and dependent upon many important factors.  A 
systematic review of 49 studies from a variety of low resource countries 
located in Africa, Asia, and Latin America found large variations in costs 
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often within the same care setting and among different care settings, but 
most of which were significant relative to middle and low income 
populations.  Despite TB related treatment having been delivered at no 
direct cost to the patient in some care settings included in this analysis, 
this study found that patients were sometimes not offered free services 
despite their availability, patients received services from private sector 
providers that were not included in national TB programs, or patients were 
responsible for ancillary medical costs such as adjunct therapy for TB 
drugs or routine hospitalization.  In addition to direct medical costs, this 
systematic review also found significant indirect costs, which included 
transportation to treatment facilities and food costs during travel.  This 
study emphasized that travel and food vouchers could be an important 
part of a successful TB program for low-income populations.  Perhaps the 
most critical factor driving cost identified across studies was the ability to 
work and earn wages.  Both treatment obligations and the physical impact 
of illness undermined the ability to work and earn normal wages placed 
patients at the highest risk of financial vulnerability.  The average cost 
breakdown across studies was as follows: 20% direct medical care, 20% 
indirect medical care, and 60% lost wages.204 
Perhaps one of the least described variables is the impact of illness 
on the ability to earn wages.  As the previous study notes, lost wages are 
one of the most important cost factors related to the impact on the patient.  
Lost wages are driven by several inputs: time away from work seeking 
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treatment including hospitalization, the impact of the disease process on 
the ability to work, and the impact of wage earning on family members and 
caregivers.  Despite this, lost wages in low to middle resource countries is 
rarely and often incompletely measured.  Based on the results from a 
systematic review, it is believed that lost wages accounts for as much as 
60% of total cost experienced by patients and their families.205  For this 
reason, the economic impact of TB was noted as a major concern 
following an interview of TB patients at an urban clinic in Bombay, India.  
This study sought to understand the perceptions of TB and the impact of a 
TB diagnosis and subsequent treatment on the daily lives of patients.  
Following intense interviews of 16 respondents, men expressed financial 
concerns including: loss of wages, reduced capacity for work, poor job 
performance, and absenteeism from work.  It is important to note that the 
surveyed men were primarily self-employed so they did not express 
concerns about losing their job, but women were more likely to be 
employed in this sample and did express that concern.  Women also 
feared rejection by their husbands while single women feared that their 
illness may reduce their chances of finding a husband, which also has 
important financial implications.206  Another focus group based study 
conducted in rural India of 304 TB patients found that an average of 83 
work days were lost following a diagnosis of TB.207  Additionally, the 
disease process itself has a significant physical toll, which has important 
implications for one’s ability to work while infected with TB.  In fact, body 
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composition changes, or wasting, is one of the most notable features of 
active disease and is attributable to a number of factors which may include 
a loss of appetite as well as metabolic changes secondary to inflammatory 
and immune responses.208,209,210,211  The relationship between wasting and 
physical impairment is well described, although the economic implications 
of this relationship are not that well understood.212,213  However, it is 
noteworthy that emerging research has identified important risk factors for 
wasting including low socio-economic status and risk behaviors 
associated with low socio-economic status, indicating the impact of 
disease is more pronounced in vulnerable populations.214  Wasting is also 
an important risk factor for mortality, which also has important economic 
implications.215  A study indicated that over 500,000 disability-adjusted life 
years are lost due to illness and mortality secondary to TB each year in 
the Philippines, with an economic cost equivalent to $145 million.216 
Several inquiries into the national TB program in China illustrate 
many of the realities of TB care as found in developing countries.  China 
provides TB related treatment to patients free of charge as the result of a 
national program developed and subsidized by the World Bank following a 
resurgence in TB rates in the 1990s.  This national program consists of a 
local delivery system on the county level and provides 6 months of TB 
therapy for treatment naïve patients and 8 months for treatment 
experienced patients along with a sputum smear test, and chest x-ray at a 
local treatment center.  Initial reports evaluating the national TB program 
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in China, early in its implementation phase, boasted positive results, 
reporting 98.4% adherence in a population of over 55,000 patients.217  
However, subsequent reports have noted that TB treatment providers 
recommend treatment courses beyond what is provided by the national TB 
program, along with additional laboratory methods, imaging studies and 
ancillary treatment such as liver preserving therapies at an additional cost 
to patients.218  A systematic review measuring direct medical costs 
incurred by TB patients in China sought to trace the relationship between 
cost and adherence and completion of TB related treatment.  Data 
extrapolated from published studies and data from Chinese and 
international organizations found that low-income patients pay within an 
average range of 42% to 119% of their annual household income for TB 
treatment in direct medical care costs.  Also, 73% of TB patients admitted 
to having interrupted or suspended their treatment, citing cost as the most 
common reason.  This study found that despite the Chinese policy of TB 
care delivered at no cost to patients, TB patients and their families are 
paying significantly and often failing to complete their treatment as a result 
of direct medical cost.219      
 Another systematic review focusing on countries in sub-Saharan 
Africa pulled direct and indirect cost data published in thirty studies from 
the following countries: Zambia, Nigeria, Kenya, Malawi, Ethiopia, 
Uganda, South Africa, Sierra Leone, Gambia, Botswana and Tanzania.  
This review included a descriptive classification of costs including those 
 62 
 
incurred in the private sector prior to patients being transferred to the 
public sector for treatment through free national TB programs.  In addition 
to private sector provider fees, additional direct costs included health 
insurance premiums, prepayment fees, and tipping of medical providers 
as practiced in Uganda.  Diagnostic, treatment and hospitalization costs 
were reported and sometimes included admission fees, culture and 
imaging costs, treatment costs, and needle and syringe costs.  Another 
descriptive cost item noted in five studies were costs associated with visits 
to traditional healers, and four studies noted the cost of food including 
special therapeutic food.  Of course, travel costs were also noted as well 
as time costs, which equated to lost work time.  Not all studies reported 
every cost category, but in many cases the presence of only one of these 
costs could easily exceed the resources of the poor and some middle-
income patients.  For example, the cost of TB care reported in Malawi 
relative to monthly income ranged from 129% to 244% in the sample 
evaluated.  More than one cost classification was present for TB patients 
in Zambia with 16% of monthly income spent on transportation costs, 66% 
spent on food costs, and a range of 10% to 132% having been allocated 
to treatment costs.  In Zambia, female patients were reported to spend 
much more on TB treatment than male patients.  In Ethiopia, 48% of 
monthly income was spent on treatment and 35% was spent on 
pretreatment.  In addition to patient cost, eight studies noted direct and 
indirect costs incurred by caregivers or guardians.  In twenty of the thirty 
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studies, direct and indirect costs associated with TB were found to be 
catastrophic for those of average income while twenty five studies found 
costs to be catastrophic for those of low income as defined as the bottom 
20%.  Therefore, a diagnosis of TB in sub-Saharan Africa can either cause 
or exacerbate poverty as well as impact the willingness for patients to 
seek care for TB.  The delay of treatment has additional implications, 
which can result in the presentation of more advanced disease and 
facilitate the transmission of disease to others.220 
Following a survey based study of national TB programs in Ghana, 
Vietnam and the Dominican Republic, direct and indirect costs incurred by 
patients were measured from a sample of TB patients who had undergone 
at least one month of therapy.  This study found the economic impact of 
TB to be significant in care settings on three different continents.  For 
example, between 27% and 70% of patients reported that they had 
stopped working as a result of their diagnosis.  Also, between 5% and 
37% sold property and between 17% and 47% borrowed money in order 
to pay for direct and indirect medical costs and account for lost wages.  
The total average costs incurred by patients in all care settings were 
equivalent to approximately 1 year of individual income.221 
The impact of TB-related expenses on accessing and adhering to 
quality care has been addressed in several reports by the World Health 
Organization (WHO).  In its report encouraging all states to adopt some 
form of universal access to healthcare resources, TB is noted as one 
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particularly devastating disease that can result in financial hardship if care 
is accessed without financial support.222  Also, a subsequent report noting 
the potentially catastrophic financial costs TB affected patients and their 
families face in many care settings due to direct and indirect health care 
costs also emphasized the need for income replacement and social 
support in the event of illness.223   
Given the consistent findings from individual studies and systematic 
reviews, the weaknesses of many national TB programs that fail to deliver 
quality and cost effective TB care has been widely documented.  As a 
result, several studies have been published to facilitate improvements in 
the allocation of TB diagnostic and treatment resources.  
A study of the national TB program in South Africa found 
insufficient resources being allocating in research and development 
despite South Africa having had the second largest incidence rate of TB in 
the world according to 2010 data.  The epidemic in South Africa has been 
facilitated by the HIV/AIDS epidemic, which has disproportionately 
affected sub-Sahara African nations.  According to the WHO, TB is the 
most common co-infection disease of HIV/AIDS and is the cause of death 
of one quarter of HIV/AIDS patients.224  Reports from sub-Saharan Africa 
reveal that TB is often undiagnosed in HIV/AIDS patients and death due to 
disseminated disease is not uncommon.225,226  South African TB 
prevention policy encourages the 1.5 million HIV/AIDS patients to receive 
first line drug isoniazid as part of active TB disease prevention therapy.  
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When this figure is combined with the nearly half million cases of active 
TB annually, this equates to nearly 2 million treatment regimens.  This 
study likewise found that South Africa is providing only a fraction of 
treatment demand due to resource constraints.227   
Research and new drug development for new treatment regimens 
have been slow.  The model has historically been to rely on higher 
resource countries to facilitate new drug discovery, but this model has not 
been effective for TB for several reasons.  First, the global impact of TB 
has been outside of high resource countries resulting in the discovery of 
new drugs having a low impact on the settings and funding for new 
therapies.  Also, high prevalence TB countries tend to be low to middle 
resource with public delivery systems in place resulting in a resource-
constrained public sector unable to pay market premiums for new 
therapies.  For these reasons, TB research and development will not 
provide a suitable return on investment as would be expected by the 
private sector in high resource countries.  Despite arguments that drug 
development should still occur due to a moral obligation, new drug 
development for TB has remained inadequate relative to global demand.  
As a result, policy makers are beginning to encourage a stronger 
investment in research and development in countries with a high burden of 
disease, offering a mathematical model demonstrating a suitable return on 
investment given the crippling disease burden in some countries.228 The 
table below provides a summary of costs of TB delivery systems.  
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Table 8: Program delivery costs for budgets and patients 
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The success of cost effective national TB programs depends on the 
availability of accurate and affordable diagnostic and treatment 
technology.  Researchers and policymakers agree that current diagnostic 
technology is inadequate to address global demand.  Given that one third 
of the world is believed to have undiagnosed disease, under diagnosis 
remains an important challenge to global TB control.  The epidemiology of 
TB and its association with the poor in both high and low resource 
countries also has financial implications for diagnostic technology.  
Therefore, the design of effective TB screening programs along with the 
use of cost effective diagnostic methods remains a common discussion 
the peer-reviewed published literature.  The appropriate use of resources 
has also been the primary endpoint for several studies examining current 
diagnostic methods. 
The New Diagnostics Working Group of the Stop TB partnership 
published a report that summarizes the current state of TB testing 
technology while summarizing the challenges in new technology 
development.  The report also included a wish list outlining the 
characteristics of the ideal testing methodology.229  A WHO report 
addressed the unmet needs of TB diagnostics offering a more detailed 
wish list for TB diagnostic test characteristics.  The WHO also described 
the need for the availability of different tests relative to care setting and 
populations.230   
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In a review specifically evaluating diagnostic technology available 
to low resource countries with a higher proportion of TB, Molicotti and 
colleagues discuss the cost implications of diagnostic methods relative to 
effectively diagnosing disease.  Modeling studies have shown 400,000 
lives could be saved annually with the adoption of rapid TB testing 
techniques with a sensitivity greater than 85% for both smear-positive and 
smear-negative cases along with a specificity of 97%.231  Given current 
technology and cost, the WHO recommends liquid culture systems in low 
resource settings.  However, the purchase and maintenance of laboratory 
instruments along the laboratory infrastructure to conduct liquid culture 
testing simply does not exist in many low resource countries.232  Instead, 
many low resource countries continue to rely on the microscopic 
examination using the Ziehl-Neelsen smear method given its low cost of 
approximately $0.50 for two sputum smear studies.  However, poorly 
maintained laboratory equipment, understaffing, and the lack of 
consistently available clean water and electricity severely compromise this 
the sensitivity of this test.  The Ziehl-Neelsen has been proven especially 
insensitive in populations with a compromised immune system and in 
pediatrics.233  Further, an important limitation of smear testing alone is that 
this laboratory method does not distinguish TB from other mycobacterium 
species or determine drug susceptibility, which contributes to 




Although many studies acknowledge the importance of cost 
effective diagnostics, especially for low and middle resource countries, few 
studies are available that standardize and measure the of cost diagnostic 
technology.  One cost study evaluated the affordability of new tests in 36 
high burden countries.  New diagnostic test types were categorized into 
four groups: rapid-sputum, non-sputum biomarker, triage test followed by 
confirmatory testing, and drug susceptibility testing.  The costs of these 
tests were estimated based on the unit cost multiplied by the number of 
tests and compared with the current spending on conventional 
diagnostics.  The conclusions of this study found that non-sputum 
biomarker testing and triage testing followed by confirmatory testing are 
affordable with current resources.  The use of rapid-sputum tests and drug 
susceptibility testing would only be possible with additional funding.  It is 
important to note that this study only considered variable testing cost, 
ignoring fixed costs such as equipment and facilities.234  In developed 
countries where the investment in additional infrastructure and equipment 
costs may not be necessary, the examination of variable cost alone might 
provide a complete enough picture.  For low resource countries, especially 
where infrastructure is lacking and equipment may be unsuitable, fixed 
costs represent a critical part of the equation.  Another challenge in 
estimating cost lies in the high variability of both unit and secondary 
material cost.  For example, smear cost data vary between $0.26 and 
$10.5 and culture cost ranges from $1.63 to $62.01.  The cost range for a 
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combination unit consisting of both smear and culture ranges from $2.27 
to $48.23.235  
In order to accurately represent cost, some studies have sought to 
measure the economic impact of TB.  Economic costs include a variety of 
characteristics beyond the variable costs associated with a laboratory test, 
but also include the investment of additional resources in order to be able 
to conduct the test properly.  These costs may be offset by the economic 
impact of the test by diagnosing TB in populations earlier or detecting the 
disease in populations in which the disease may be undiagnosed.  In 
these cases, economic cost would be heavily impacted by the initiation of 
therapy earlier, the reduction of transmission, fewer wages lost, and fewer 
complications of treatment.  Sohn and researchers evaluated several cost 
studies in a review noting the difference in financial versus economic costs 
in TB diagnostic testing.  According to this assessment, the cost of 
diagnostic testing extends well “beyond the simple boundaries of current 
consumable costs and simple comparisons of equipment cost.”  Instead, 
the need to measure economic cost as a complete assessment of cost is 
necessary to establish evidence-based guidelines.236 
Drug Resistance Cost 
The cost of TB treatment is exacerbated following a diagnosis of 
multi-drug resistant TB (MDR-TB) or extreme drug-resistant (XDR-TB).  
MDR-TB is defined by drug resistance to specific first line therapies 
isoniazid and rifampin.  XDR-TB is likewise resistant to first line therapies 
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in addition to any fluoroquinolone and one of the following three injectable 
second-line drugs: amikacin, kanamycin, and capreomycin.237,238,239  In 
2010, an estimated .4% of TB cases were drug resistant worldwide, which 
equates to 440,000 cases annually.240  This number is expected to 
increase as inadequate treatment coupled with the transmission of drug 
resistant strains of disease are expected to continue.  Official numbers, 
however, remain unreported.  According to the WHO, less than 30,000 
cases of M/XDR-TB were reported in 2008, which is believed to represent 
only 7% of new cases that same year.  Also, WHO guidelines for the 
management of M/XDR-TB were unmet in 60% of reported cases.241  
Treatment costs for X/MDR-TB alone range from 9 to 25 times the cost of 
treating drug susceptible TB, and treatment courses can be up to 3 times 
standard duration.242,243   
 The financial impact of MDR-TB disease on the patient and his or 
her family is not well described.  A 2010 study interview-based in Ecuador 
documented total out of pocket treatment costs reported by patients 
following 2 months of therapy, noting the average for drug susceptible 
patients with TB at $960 as compared to $6880 for patients with MDR-TB.  
Of the 118 patients interviewed for this study, only 14 patients were 
infected with MDR-TB.244  In national budgets, the relatively low incidence 
of MDR-TB and XDR-TB commands a disproportionately high percentage 
of national TB program budgets.  In South Africa, for example, MDR-TB 
accounted for 2% of TB cases in 2011 while consuming over 30% of the 
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total national budget during the same year.245  The continued spread of 
MDR-TB and XDR-TB in low-resource countries can be potentially 
devastating to governments with high TB prevalence along with increasing 
MDR-TB and XDR-TB.  In some countries, these direct medical care 
expenses are shared between governments and TB patients and their 
families, resulting in both bankrupting national governments and 
facilitating poverty in vulnerable populations.  Also, indirect medical costs 
can be even more economically devastating as compared to drug 
susceptible TB.  The consequences of more severe disease are longer 
treatment courses resulting in longer periods of travel, food costs, and lost 
wages.   
A systematic review evaluating the cost of MDR-TB treatment along 
with identifying cost drivers following the assessment of 420 studies 
published in five languages found only four studies with quality data that 
could be extracted and adjusted to American dollars and international 
dollars as well as adjusted for inflation for comparison within a common 
year.  These four studies contained cost data from care settings in Peru, 
the Philippines, Estonia, and Russia, noting that the largest influence on 
cost was hospitalization.  Many national TB programs use hospital care 
settings to ensure patient compliance and prevent disease transmission, 
but the authors note that the use of outpatient care settings represent a 
better use of resources even with the added expense of food and travel 
vouchers.  The use of vouchers has been proposed by the WHO to reduce 
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the impact of indirect cost on patients and their families but also better 
ensure patient compliance to treatment courses.246  The second largest 
cost driver across studies was the use of expensive second line drugs, 
which is an unavoidable expense for patients with resistant disease.  The 
authors suggest that despite the cost of expensive therapies, MDR-TB 
management delivered in an outpatient setting can still be cost effective in 
low and middle resource countries.247  This study also offered important 
implications for the availability of cost data specifically for MDR-TB when a 
systematic review yielded less than 1% of studies evaluated that included 
enough quality data to be included.  Clearly, the cost of MDR-TB has not 
been adequately measured.  A literature review searching for comparable 
cost data for XDR-TB revealed no reliable data from any care settings in 
the developing world.  See the table below for a summary of costs 
measured in the literature associated with treating drug resistant TB. 
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TB in the developed world 
The epidemiology of TB in the developed world exists in sharp 
contrast to that of the developing world.  In local populations, TB rates in 
high resource countries are associated with several distinct factors.  First, 
the use of immune suppression therapies for cancer treatment, post-
transplant therapy or immune modulation therapy for auto-immune 
diseases have created a risk group that only exists in resource rich 
countries where advanced therapy options are widely available.  Also, 
comorbid conditions that affect the immune system including underlying 
pulmonary diseases, diabetes mellitus,248 and advanced HIV/AIDS is a 
risk factor for active TB all over the world including the industrialized 
west.249  Behavioral factors play an important role such as diet and 
malnutrition, alcoholism, and smoking tobacco, particularly in vulnerable 
populations.250   
In the industrialized west, social determinants of health are strong 
predictors of TB infection. In a master’s thesis, the disparity of disease 
incidence in local populations was studied in both Canada and New 
Zealand.  In both countries, a higher incidence of TB has been recorded in 
local aboriginal populations in Alberta, Canada as well as the Maoria and 
Pacific populations in New Zealand.  This study identified key individuals 
involved in the transmission of TB within their communities based on 
contact tracing and strain analysis, noting that substance use and a delay 
 75 
 
in accessing treatment were common characteristics from both 
populations.  The author notes that future research in this area might 
solidify this association by studying the impact of other characteristics of 
vulnerable populations such as poverty and unemployment.251  Despite 
the presence of these risk factors in key populations in North America and 
Europe, TB rates have remained stable or declined in local populations.   
Immigration remains one of the strongest predictors of TB infection 
in North America and Europe, particularly those who migrated from high 
HIV and TB burden countries.  In fact, more than half of active TB cases 
are diagnosed in immigrant populations.252,253  In the UK, the incidence of 
disease in local populations has fallen 5% between the years 1998 and 
2008 and likewise increased by 94% in foreign-born populations during 
the same years.254  In the years 2000-2013, TB cases in locally born 
populations have actually decreased by half in the US, Canada, and 
Europe while rates among immigrant populations have increased.  The 
European Centre for Disease Prevention and Control and the WHO 
Regional Office for Europe released a joint report in 2015 noting that 28% 
of TB cases in Europe in 2013 were in foreign-born populations.255  In 
Western Europe, a 2010 report estimates this average is excess of 
40%.256  In some states, the prevalence of disease in the foreign-born 
account for a resounding majority: Luxemburg (94.7%), Sweden (88.7%), 
Malta (88.0%), Norway (86.0%), Cyprus (85.4%), Netherlands (73.9%), 
Switzerland (75.3%), and United Kingdom (70.1%).257  In the United 
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States, the CDC reported that 64.6% of TB patients were born outside the 
US in 2013.258  Immigration rates to the US are expected to continue if not 
increase in coming years.  Each year, approximately 450,000 persons are 
admitted to the United States on an immigrant visa, and 50,000–70,000 
are admitted as refugees.259   
Migrant Populations 
Immigration status alone is not a predictor for TB because the 
prevalence of disease is much more pronounced in select immigrant 
groups than others.  Among the immigrant populations at a particularly 
high risk are those from moderate to high TB burden countries.  Also, 
immigrants having arrived within 5 years, termed “new entrants,” are 
another important risk group.260  In the UK, new entrants are believed to 
account for an estimated 50% of TB cases in the foreign-born 
population.261  Finally, immigrant populations with comorbidities represent 
important risk groups for developing active disease such as HIV/AIDS.262  
According to the European Centre for Disease Prevention and Control and 
the WHO Regional Office for Europe, data were available in 36 countries 
regarding TB and HIV noting a co-infection rate of 7.8%.  The 2012 joint 
analysis reported a co-infection rate of 6.1%, which confirms the 18% 
increase in co-infection rates annually that has occurred in Europe since 
2004.  It is important to note that this figure only includes data from 36 
reporting countries, and only 219,095 of 324,084 TB patients had a 
documented history of HIV testing.  Therefore, it is likely that this 
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documented co-infection rate is under-reported.263 
The presence of TB in immigrant populations can be explained by 
three important pathways.  First, immigrants arriving to destination 
countries may have been previously exposed and infected with active 
disease while residing in their home countries and represent cases of 
active disease upon arrival.  Also, immigrants may be infected with latent 
disease upon arrival, which activates following entry into destination 
country.  Third, immigrant populations acquire TB from local transmission 
following exposure most likely to peers from moderate to high burden 
countries.264  Immigration from these countries is expected to remain a 
key factor in TB epidemiology as the United Nations note immigration 
figures in 2013 alone was 232 million, representing a 50% increase over 
the preceding two decades.  The 2013 UN report explains migration is 
expected to continue to increase secondary to globalization, conflict and 
financial and economic reasons.265   
The impact of immigration on TB rates is expected to be more 
measurable given the recent refugee crisis secondary to current conflicts 
in Iraq and Syria.  According to Amnesty International, over half of Syria’s 
population is currently displaced.  While some remain displaced within 
Syria, the majority of refugees reside in neighboring countries including 
Turkey, Lebanon, Jordan, Iraq and Egypt.266  In 2015, European countries 
noted a major influx of Syrian refugees into Europe, coming from both 
Syria and refugee centers in neighboring countries.  The number of first 
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time applicants for asylum in European Union countries more than 
doubled from 563,000 in 2014 to almost 1.26 million in 2015.  Syrian 
refugees represented 29% of the total number of first time applications in 
2015, 14% from Afghanistan, and 10% from Iraq.267  The US has pledged 
to accept 10,000 Syrian refugees in 2015, increasing allowances in the 
three subsequent years for an average of 70,000 to 85,000 annually.268  
As of February 2016, Canada has accepted over 25,000 Syrian 
refugees.269  These numbers exist in excess of regular and projected total 
immigration numbers including asylum seekers, and represent important 
implications for immigration, population demographics and resulting public 
health policy in many countries.  Regular immigration in the US includes 
approximately 450,000 persons using immigrant visas and between 
50,000 and 70,000 as refugees.270 
Many industrialized states have created and executed extremely 
successful public health programs that have controlled TB rates as evident 
in its decline in local populations.  These programs seek to include the 
diagnosis of TB in early stages of disease, initiate treatment while 
ensuring patient compliance, and trace possible transmission contacts.  
However, this approach is only relevant in cases in which TB is acquired 
following arrival to destination countries and fails to identify and treat 
cases of latent and active disease present in immigrant populations during 
the migration process.  Policies specifically designed to target migrant 
populations represents an emerging need in many countries as part of a 
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more comprehensive TB program aimed at reducing the burden of 
disease both local and migrant populations.  
In the US, programs for screening and managing related treatment 
for immigrants diagnosed with TB is managed according to the Directly 
Observed Therapy, Short-course (DOTS) national framework.271  DOTS is 
an approach to TB surveillance and treatment recommended by the WHO 
that requires first an investment from all levels of government internally as 
well as international partnership in order to enhance TB monitoring, 
surveillance and training.  First, DOTS emphasizes the need for smear 
microscopy followed by culture and drug susceptibility testing for the 
accurate diagnosis of disease as well as the identification of drug resistant 
cases.  Next, DOTS calls for a standardized treatment regimen of six to 
nine months in total duration, the first two months of which should be 
directly observed by a healthcare worker or community health worker.  
DOTS also calls for a standardized surveillance and monitoring systems. 
The overall goal of DOTS is to ensure that TB is cured in diagnosed cases 
following an appropriate treatment course, which will also prevent further 
transmission as well as the facilitation of drug-resistance.272,273   
Many aspects of TB screening of immigrant populations is 
controversial.  For starters, the use of DOTS as a comprehensive testing 
and treatment program has significant costs for countries with a large 
inflow of immigrants when the supervised treatment portion of the program 
has not been well proven.  These findings were consistent with a 
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previously published multicenter study of nearly 500 patients in which 
three arms were evaluated: 70 were assigned DOTS with direct 
observation of treatment by health workers, 165 were assigned DOTS with 
direct observation of treatment by family members, and 162 were 
assigned self-administered treatment.  Outcome measures were cure or 
treatment completion.  This study found similar outcomes in all three arms 
with cure or treatment completion rates of 67%, 62%, and 65%, 
respectively.  This was an important study that failed to demonstrate 
DOTS as a superior strategy over other treatment programs.274  In a 
recent retrospective comparative study of 150 patients, the treatment 
success rate of 72% was equal in a sample of 75 who underwent 
compulsory supervised treatment versus the remaining 75 whose care 
was delivered in a self-administered model.  Given that DOTS remains 
unproven as a superior approach to the administration of TB therapy, 
some policymakers recommend its use only after patients fail self-
management.275 
Many industrialized countries have designed TB screening 
programs that are integrated with immigration procedures as a result of 
this emerging need.  One of the most common screening methods used is 
chest radiography for the detection of active disease.276  Applicants 
seeking entrance into the US as an immigrant or refugee status are 
required to undergo a medical examination prior to their arrival.  The 
Department of State appoints the physicians who perform the 
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examinations according the Technical Instructions provided by the CDC’s 
Division of Global Migration and Quarantine (DGMQ).  Beginning in 1991, 
chest radiography has been used for applicants over the age of 15 years.  
Chest x-ray findings suggestive of pulmonary TB were further evaluated 
using sputum smears until 2007, when the CDC followed the sputum 
smear with cultures.  In 2012, 60% of the TB cases diagnosed using 
cultures were in applicants with negative smears.   
Meanwhile, the universal use of chest x-ray for immigrant screening 
has been widely debated in the literature.  Most evidence does not support 
its use due to unacceptable sensitivity, specificity and cost-
effectiveness.277  One systematic review and meta-analysis in which 22 
relevant publications were analyzed agreed that chest radiograph did not 
offer the acceptable yield of an effective screening tool, noting that of the 
2,620,739 imaging studies only 5,446 cases of active disease were 
diagnosed, representing one diagnosis in 481 chest radiographs.278  
Another report noted that among the important diagnostic challenges is 
that chest radiography depends on access to complementary resources 
such as equipment and the availability of experienced medical personnel 
who possess the skills to identify active disease with an atypical 
appearance.279  Further, the incidence of false positives secondary to 
technical problems, lung scarring, the presence of other underlying 
pulmonary disease, or previous TB with associated healed cavitary lesions 
is another important driver of program cost.  These factors commonly 
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result in further medical evaluation and additional costs.280  For these 
reasons, untargeted chest radiography has been disproven as part of a 
cost effective screening program.   
The well documented challenges of diagnosing active TB has 
resulted in a lively discussion in the peer-reviewed medical literature and 
among policy makers theorizing more effective TB treatment and 
diagnostic programs in immigrant populations.  This discussion has, in 
some cases, resulted in policy changes in some countries. Following a 
review of several countries in North America and Europe, it is evident that 
a lack of uniformity in screening methods and goals exists in developed 
countries.  This review implies that no proven standard of TB control exists 
that effectively balances TB risk management with cost in immigrant 
populations.  The most common screening practice is the single-level, one 
time screening of migrants for active disease.  These largely superficial 
and ineffective screening programs remain the most common despite low 
yield, which is perhaps the most important measure of program 
effectiveness.281 
The literature offers a variety of other suggestions for more cost 
effective screening programs for immigrant populations.  One important 
suggestion is to target chest radiography to migrant populations with risk 
factors for disease.  In this case, imaging may only be recommended for 
migrants from moderate to high resource countries or with personal risk 
factors for disease.  The screening process in Switzerland exists as a 
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model for reserving chest radiography for select populations based on 
results from a pre-screening interview and associated questionnaire.  The 
Swiss program utilizes a nurse to conduct the interview in which medical 
history and family history are recorded and the results are measured 
against the risk associated with country of origin.  This program reduces 
the number of migrants undergoing chest radiograph based on risk 
stratification.282  
A 2013 study that evaluated a variety of screening approaches 
demonstrated that screening for active disease in immigrant populations is 
one piece of what should be multi-faceted program to detect both active 
and latent disease.  Further, the WHO recommended in a 2014 report that 
migrants from high burden TB countries to be screened for latent disease 
as well.283  Further, findings from a 2016 review suggest that effective 
screening can only be accomplished through multiple, inter-linking 
elements including pre-arrival screening of active disease in addition to 
post-arrival screening of latent disease targeted to migrants from 
moderate to high burden TB countries.  The authors acknowledge 
considerable challenges with the implementation of a multi-level program, 
but urge more research in TB screening program design and effectiveness 
in order to better establish international evidence based guidelines.284  
Given that the presence of latent disease is another important 
pathway to infection for immigrant populations, some policy makers have 
also suggested immigrant screening for latent disease.  However, few 
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studies have been published that analyze the effectiveness of screening 
programs for latent disease. 
TB skin testing (TST) has been the screening tool of choice for a 
variety of settings including but not limited to healthcare and restaurant 
workers in addition to immigrant populations.  The majority of the limited 
data evaluating the potential utility of latent disease screening programs in 
immigrant populations relies on the TST.  A study of refugee populations 
evaluated the impact of screening for latent disease using a TST prior to 
entrance into the United States as a means of reducing the incidence of 
active TB in this population.  This was a cost benefit study using a 
decision tree with multiple Markov nodes to determine the total costs and 
number of active TB cases in 55, 35, and 20% TST positive under two 
models: no overseas screening and overseas screening and treatment.  
Also, refugees were stratified by risk based on the prevalence of TB in 
their country of origin into the following categories: high, moderate, and 
low TB.  Using the hypothetical 100,000 refugees over a one year period 
from countries with high, moderate, and low TB prevalence, the authors 
estimated that screening for latent TB would prevent 440, 220, and 57 
cases in the US during the first 20 years after arrival.  Further, the authors 
emphasized a cost savings associated with the screening program of $4.9 
million for refugees from high burden TB countries when the cost of 
treatment was considered, $1.6 million for countries with moderate TB 
prevalence, and $780,000 for low TB prevalence countries.  The authors 
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noted that these cost savings were conservative given that the cost of 
managing additional cases secondary to the transmission of active TB 
from these cases was not considered in this model.286 
One important consideration of screening for latent TB is the 
several functional challenges surrounding the use of the TST.  First, the 
test is read between 48 and 72 hours following administration, which 
requires a separate visit.  Also, the reading of results may be open to 
interpretation.287  The other potentially critical challenge is relying on the 
TST especially when screening immigrants from high burden TB countries 
is previous exposure to the Bacillus Calmette–Guérin (BCG) vaccine.  In 
many high burden TB countries, the BCG vaccine is administered to 
babies as a population level prevention strategy.288  In fact, the WHO 
recommends that BCG be administered to all children born in high burden 
countries.289   In low and moderate burden countries, the use of BCG 
vaccine is targeted to at risk populations.  Babies in these populations are 
sometimes vaccinated.  Adults can be vaccinated as well.  The vaccine 
protection timeframe is between 10 and 20 years.290  One major 
consideration, however, is research indicates that exposure to the BCG 
vaccine can generate a false-positive TST.  Also, those with active NTM 
infection are likely to yield a false positive result.291,292  Further, TST may 
generate false negatives in hosts who are pregnant, or 
immunosuppresses due to malignancy, nutrition, HIV/AIDS, or those 
receiving immune modulating therapy given the reliance of the TST on the 
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ability of the immune system to generate a response.293,294,295 
Another important screening tool for latent disease are IFN-gamma 
release assays (IGRAs).  Currently, two blood assay tests are 
commercially available: Quanti-FERON-TB Gold In-Tube (QFT-GIT; 
Cellestis, Carnegie, Australia) whole blood enzyme-linked immunosorbent 
assay (ELISA), and the T-SPOT.TB assay.  Limited data are available that 
compares TST with assays in migrant populations, noting that Quanti-
FERON-TB seems to have a lower detection rate than the T-SPOT.TB 
assay.  It is important to note, however, that both assays seem to be less 
sensitive than TST.296  Also, few data are available to evaluate the use of 
IGRAs as a screening tool, but emerging data indicates that blood assays 
are not reliable in this setting, especially in cases in which latent disease 
has been previously treated or there has been a history of TST.297 
In a master’s thesis, the cost effectiveness of screening tools 
including TST and blood assay tests for latent infection were evaluated in 
the Netherlands, a low burden TB country, in immigrant populations who 
participate in contact investigations.  Using decision tree analyses that 
measured direct medical costs for two years following screening for latent 
disease, this study measured two years of cost analyses following initial 
contact investigation in which the use of TST was validated in healthy 
immigrant contacts.298  
Perhaps the most important component of a successful screening 
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program for latent disease is the ability to provide and complete treatment 
in positive cases.  This depends on two primary factors.  First, adequate 
public resources need to be allocated to provide treatment in all cases of 
latent infection.  Second, a concentrated effort is necessary in order to 
assure that immigrant populations remain compliant during long treatment 
courses.  This remains a particular challenge given that these populations 
tend to be vulnerable and not always able to comply with office visits and 
medication.  Also, in many migrant populations people move frequently, 
which requires a transfer of care during long treatment courses, which 
increases the likelihood of patients discontinuing therapy.  Further, cultural 
issues in many populations play an important role.  In a study of Hispanic 
migrant farm workers entering the US, adherence to treatment was found 
to be an important challenge noting that less than half agreed to even 
initiate therapy citing cultural barriers.299 
These programs all share an important limitation in that they are 
confined to a screening population of migrants that legally enter 
destination countries and submit to the legal entry process.  Population 
screening is not available for the thousands of migrants who enter 
destination countries illegally.300  The Department of Homeland Security 
estimates 11.4 million unauthorized immigrants were living in the United 
States on January 1, 2012.  This figure has not significantly changed from 




Nontuberculous Mycobacterium (NTM) represents an emerging 
public health challenge.  In the developed world, NTM infection rates have 
risen significantly in recent decades secondary to many factors including 
population aging, the availability of immune suppressing therapies in 
resource rich healthcare delivery systems secondary to cancer, 
autoimmune disorders and post-transplant therapy.  Also the worldwide 
HIV/AIDS epidemic continues to facilitate the prevalence of NTM in the 
developed world as well as the undeveloped world.  Even so, cost 
information measuring direct and/or indirect costs as well as economic 
impact remains extremely under measured.  The few available studies that 
attempt to describe the cost of care of NTM in limited care settings note 
the lack of data available and encourage other research in this largely 
unappreciated global health crisis.  In the undeveloped world, even less 
data are available regarding all aspects of NTM including epidemiology 
and cost.  The majority of discussion on NTM in the developing world 
addresses the disease as it impacts the diagnosis and treatment of TB.  
These studies emphasize the challenge of appropriate treatment for TB in 
high burden clinical settings when the potential confounding case of NTM 
presents.  
NTM in the underdeveloped world 
The epidemiology and cost of NTM in the developing world is an 
emerging area of research in the field of mycobacteriology.  Many 
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important challenges exist that has made research in this area difficult.  
For starters, mycobacterial disease is diagnosed in developing countries 
based on clinical and radiological findings.302  Diagnostic technology is not 
usually available in these care settings that would differentiate NTM 
species from TB or other diseases.  Given that NTM often resembles TB 
in disease presentation and radiological features, many researchers 
believe that NTM is often mistaken for TB, particularly MDR-TB, following 
a treatment failure.  This theory has important implications for resource 
management in low resource care settings as well as antibiotic 
stewardship.  For these reasons, no estimates of NTM rates in low 
resource countries are currently available.  What little data exists must be 
pieced together from studies conducted of TB in low resource countries in 
which the discovery of NTM is incidentally reported.303  No cost 
information is available except also in cases in which NTM was 
misidentified and noted to impact the cost of treatment.   
Emerging literature is addressing the burden of NTM disease in low 
resource countries as its clinical importance relating to other health 
challenges in these care settings has become increasingly apparent.  
First, the association of NTM with the HIV/AIDS epidemic is well described 
in most every care setting.  The importance of this relationship is amplified 
in developing countries in sub-Saharan Africa in which HIV/AIDS rates 
have been reported as high as 25%.  Further, the unavailability of 
important therapies that have been shown to slow down or stop the 
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progression of HIV to AIDS in many low resource care settings is also an 
important contributor to the epidemiology of NTM.  In a 2007 dissertation 
in which NTM was studied in Zambia, one of the world’s poorest countries, 
this particular study emphasized the importance of HIV/AIDS as a risk 
factor for NTM in Zambia as well as neighboring countries in the region.  
This dissertation featured a study population of 64 patients of mixed HIV 
status who had been chronically ill for more than two weeks, thirty of 
which were identified as infected with mycobacterium disease using liquid 
culture.  Only eight patients from this sample were found to be infected 
with TB as compared to twelve who were infected with NTM.  Of the NTM 
species identified, seven patients were diagnosed with M. szulgai, three 
patients had MAC, one patient had M. simiae and the remaining one 
patient had M. terrae.  One interesting finding of this study was the 
presence of M. szulgai, which represents an NTM species that strongly 
resembles TB in disease presentation as well as DNA.  In this particular 
sample, five patients with NTM disease caused by M. szulgai were given 
anti-TB therapies and three cases were noted as responsive.  It is also 
important to note that ten isolates in this study were unable to be 
identified.  The major conclusion of this study was that TB is grossly over 
diagnosed in Zambia, which must be addressed by improving access to 
better diagnostic technology as well as the incorporation of diagnostic 
scoring systems and algorithms to be validated for use in low resource 




In a study conducted in the high burden TB country Mali where 
most patients receive empiric treatment for TB, clinical samples from 142 
patients were evaluated by smear, culture and drug susceptibility testing.  
This study had two arms: 61 patients who had undergone treatment for TB 
and 17 patients who had no previous exposure to anti-TB drugs.  Of the 
11 patients who tested positive for NTM, all were identified from the 
treatment experienced group.  It is important to note that all 11 candidates 
had been identified as candidates for expensive second line anti-TB 
treatments.305 
In low resource countries with reliable access to laboratory 
diagnostics, the low cost option of sputum smears remains widely used.  
The issue with smears, however, is that TB and NTM cannot be 
differentiated without follow up studies including cultures or molecular 
methods of species identification.306  In China, 80% of laboratories 
designated for TB diagnostics lack the equipment necessary to perform 
culture or other methods of species identification leading to a diagnosis of 
NTM infection.307  The misdiagnosis of NTM infection has important global 
consequences, leading to inappropriate treatment, elevated cost, and the 
facilitation of continued antibiotic resistance. 
In a study conducted in Tehran, Iran, sputum smear and culture 
were performed on clinical isolates collected from 105 patients.  
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Microbiological testing was repeated twice to assure accuracy.  Also, PCR 
was performed on all patients and species identification was performed by 
PCR and routine identification tests for all culture-positive cases.  In this 
study, 12 isolates, (11.43%) were identified NTM species.  It is important 
to consider that clinical appearance was similar in patients.  For example, 
cavitary lesions were present in 41.7% of the cases.308 
Another study conducted in the southwest portion of Iran was a 
retrospective evaluation of 117 consecutive samples collected from 
patients diagnosed with MDR-TB.  Patients who met criteria for inclusion 
had been administered between two and three months of a first line anti-
TB regimen but had not achieved sputum conversion.  A total of 35 
patients in this sample had isolates that were identified as an NTM 
species, and 32 of these patients met American Thoracic Society (ATS) 
and the Infectious Diseases Society of America (IDSA) criteria for active 
NTM disease.  Underlying disorders that represent risk factors for NTM 
were present in 32 patients and included active malignancy, organ 
transplantation, HIV, chronic renal failure, and diabetes mellitus.  Only 
three patients diagnosed with NTM in this study had no known risk factor.  
This study also evaluated clinical outcomes for 27 patients retrospectively 
identified with NTM for which this data was available.  Ten patients were 
noted to have poor outcomes, six of which were documented as treatment 
failures and four died during the treatment course.  The remaining 17 
patients for which outcome data was available was noted as cured, 
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although the authors admit that outcome data was difficult to ascertain and 
is likely inaccurate.  The importance of this study is that it demonstrated 
that NTM was identified in 30% cases that had been misdiagnosed with 
MDR-TB, which represents a figure that is higher than the previous reports 
from Iran.  It is also important to note that given this study being limited 
only to MDR-TB cases, the case of mistaken identity in mycobacterial 
diseases is likely a much bigger problem than current literature has 
proven. The authors of this study ask an important question, is MDR-TB 
really NTM?309 
A study conducted in Nigeria found that of the 1603 patients with 
assumed TB, only 444 yielded a positive culture result following laboratory 
microbiological studies.  Of these, 69 isolates were found to be infected 
with NTM.  This study also found that NTM was more frequently 
diagnosed during the season of the year characterized by the presence of 
dust, validating environmental exposure as an important transmission 
pathway.  Also, the presence of NTM infection in younger hosts was 
frequently associated with the presence of comorbid HIV/AIDS as 
compared to those older than 35 years.310  
The burden of NTM in low resource countries has been studied 
mostly in the context of identifying functional barriers in the appropriate 
management of TB.  Due to the similarities in symptomology coupled with 
the difficulty of diagnostics when relying merely on smears, the two are 
easily confused in low resource settings, leading to improper treatment, 
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increasing costs and facilitating further drug resistance.  See the table 
below for a summary of NTM studies from the underdeveloped world. 
Table 10: NTM studies in the underdeveloped world 
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NTM in the developed world 
The relationship between TB and NTM in the developed world has 
been dynamic in recent years.  While TB rates in North America, Europe 
and parts of Asia have been steadily declining, the prevalence of NTM 
disease in the same care settings has exploded.  To illustrate, NTM 
infection prevalence in North America was estimated to be between 1.6 
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and 1.8 per 100,000 in the 1980s, with reports published in 2007 
estimating prevalence of 14.1 per 100,000.311  It is likely that this number 
is even greater.  A 2014 study sought to establish the relationship 
between NTM and TB in different care settings all over the world.  A total 
of 16 regions were evaluated including areas in Canada, the US, western 
Europe, Australia, Greece, Czech Republic and Japan, and the decline of 
TB alongside the incline to NTM was noted in the majority of regions 
based on data published in 22 studies.  The authors offered several 
theories for this relationship.  First, the existence of some degree of cross-
immunity between different mycobacterial species could be a 
consideration if both diseases were affecting similar populations.  Given 
that TB and NTM affect characteristic populations that do not intermingle; 
this explanation does not explain the trend particularly in North America 
and Europe.  Another theory is related to stages in modernization.  In 
North America and Europe, some of the causal elements that created a 
surge in TB rates in the nineteenth century urban crowding and issues 
with sanitation secondary to industrialization.  In many of these modern 
cities, significant progress has been made to improve urban crowding and 
sanitation with improvements in ventilation and public water delivery 
systems.  Given that NTM species have been confirmed in a variety of 
water samples including municipal water pipes and can be theoretically 
transmitted through aerosolized water from showers and hot tubs, it is 
conceivable that modern advances particularly in water delivery systems 
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have facilitated the transmission of NTM.  Of course, improvements in 
laboratory methods that may have misdiagnosed NTM as TB may also 
play a critical role.  Also, population aging and the age of immune-
compromising conditions and drug therapies also play an important 
role.312  Finally, the worldwide HIV/AIDS epidemic has had an impact on 
the prevalence of disease in the developed world as well as North 
America and Europe.313 
NTM and Cost 
A total of four studies have been published that attempt to measure 
the cost of NTM infection in western care settings.  In the United States, a 
small cohort study of 27 patients with pulmonary NTM found an annual 
antibiotic therapy cost of $5,196 for those infected with MAC and $11,796 
for M. abscessus.  The median total per patient drug cost was reported at 
$19,876 Also emphasized in this study, the cost of treating different types 
of NTM species can fluctuate due to variations of antibiotic cost.  For 
instance, M. abscessus was noted to be associated with higher treatment 
cost as well as the use of intravenous antibiotic therapy over oral.  
Ballarino noted that given cost data is limited in the literature for NTM, the 
use of a more established disease such as HIV/AIDS given its chronicity 
and high medication cost might be an effective proxy for NTM.314    
A retrospective chart review was conducted in Ontario, Canada of 
pulmonary NTM to determine outpatient treatment costs in Canada.315  Of 
the 177 patients identified in this study, costs were calculated for the 91 
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who underwent treatment for an average duration of 14 months.  
Researchers found that annual cost was $5,000 in Canadian currency 
adjusted to 2008 value and antibiotics were responsible for 70% of total 
cost.  It is also important to consider that over 40% of patients had been 
diagnosed with pre-existing COPD, and an even higher proportion of 
patients had been diagnosed with obstructive airway disease.  Also noting 
the unavailability of cost data for NTM, Leber and Marras suggest using 
diabetes mellitus as a proxy for measuring cost.316 
Perhaps the most comprehensive studies currently available are 
the two that used national data to estimate and report national 
epidemiological and cost data.  The first is a state specific population 
based study using Medicare data along with national survey data.  Strollo 
and researchers used a 5% sample size of the Medicare Part B database 
during the years 2003 through 2007 in order to establish an annual 
prevalence, and applied these averages to census data from 2010.  
According to this study, an estimated $815 million was spent on NTM care 
in 2010, 87% of which was spent on hospitalizations and 13% on 
outpatient management.  This study also estimated that 76% of direct 
medical costs was used for antibiotic therapy.  Given that this data would 
only include Americans over the age of 65 years, this study relied on 
previously reported epidemiology in peer-reviewed literature in order to 
estimate the number of cases in this age group.  Cost was also estimated 
based on figures reported in other studies and adjusted to the 2014 value 
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of the U.S. dollar.  Further, cost figures reported in this study only included 
one medical encounter per year per patient.  For inpatient estimates, cost 
would only include one hospitalization, which may be incomplete given 
that NTM infection has high rates of recurrence and other complications 
that often result in readmissions.  For outpatient data, this study only 
included one NTM-related visit per patient per year, which is more likely to 
be incomplete given the chronic nature of NTM infection and its 
requirement of routine outpatient visits.  Also, the need for close 
monitoring of patients undergoing treatment for NTM is necessary in order 
to both measure treatment success and identify adverse reactions quickly 
that are common during an NTM treatment course.  Although this study 
boasts of being the very first to provide state level NTM epidemiological 
and cost data, the figures reported represent merely estimates that are 
likely significantly lower than actual figures.  Despite this, the value of this 
study is its demonstration of NTM as a substantial disease burden with 
high financial costs.317  Another national study measured epidemiological 
data and cost associated with the management of ten waterborne 
diseases.  The most common pathogens in this study associated with 
disease were NTM along with giardiasis, cryptosporidiosis, Legionnaires’ 
disease, and otitis externa. This study used national data available from 
the CDC that included claims data from Medicare and Medicaid for the 
most recent two-year period available during the study period.  Medicare 
data available through the CDC was accessed through Marketscan® and 
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was available for the years 2006 and 2007.  Multi-State Medicaid 
databases were available through the CDC from Thomson Reuters from 
the years 2004 and 2005.  From 3,684 hospitalizations and 341,157 
outpatient visits, NTM was found to be among the most important of 
waterborne disease representing the cause of disease in 21% of 
immunocompromised patients, second only to cryptosporidiosis at 24%.  
Patients with NTM had the longest reported hospital length of stay at an 
average of 10.5 days.  Also, pulmonary NTM was the most expensive 
disease to manage in an outpatient setting with collections ranging from 
$311 from Medicaid patients to $1848 for patients with commercial 
insurers.  These values represents the amount collected from payers per 
visit.  Also, NTM represented the second highest average hospitalization 
cost with pulmonary infection collections ranging from $12,725 for 
Medicaid to $37,579 for commercial insurance per episode.  For 
pulmonary NTM, this study recorded a total of 22,210 cases, 14,210 
(65%) were managed in an outpatient setting with the remaining 7,659 
(35%) represent hospitalized patients.  The average hospitalization 
collection reported in this study was $25409, and the average outpatient 
cost was $1374.  It is important to note that this figure did not include 
laboratory testing costs.  The purpose of this study was to highlight the 
significance of waterborne disease given the near-universal exposure to 
multiple water sources that can lead to significant costs in the event of a 
community-wide outbreak.  However, this study had several important 
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limitations.  First, many of the diseases evaluated have several routes of 
transmission so the impact of waterborne diseases remains unproven.  As 
is the case with most studies, measuring the total economic burden of 
diseases that includes mortality and disability, work and time loss, and 
chronic sequelae are difficult to measure, so this study that seeks to 
establish the costs of direct medical care only will always be incomplete.  
In this particular study, some aspects of direct medical costs had to be 
estimated as some outpatient data was unavailable.  Also, this study was 
limited to patients with Medicare and Medicaid as payers for outpatient 
data, which has important patient selection implications for age and 
demographics.318   
Currently available data is limited to four studies that measure 
some aspects of direct cost for pulmonary NTM using data obtained from 
different care settings and patient populations.  Also, these costs are 
represented in different currencies and inflationary values.  As a result, 
cost findings for all four studies have been represented as an average per 
patient cost value and adjusted to US currency using Google currency 
converter319 and 2016 value using the Consumer Pricing Index calculator 
available through the US Bureau of Labor and Statistics.320  These 
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Other presentations of disease such as dissemination or bone and 
joint infection site can actually be more costly to treat.  The Collier at al 
study does offer some limited data on general NTM infection, but does not 
define the site of infection.  Also reported in this study is limited cost data 
for disseminated NTM infection.  Unlike the body of literature measuring 
various aspects of TB and cost, similar data is unavailable that measures 




NTM is an emerging public health problem in the US and the world 
for which very little has been published in the current body of literature.  
Also, given that NTM is not a reportable disease in the US, rates of 
infection are estimated and pieced together from various sources as no 
central epidemiological or surveillance data exists.  In other developed 
countries, the burden of the rising rates of NTM infection is likewise not 
understood.  In the developing world, NTM is largely ignored and likely 
managed as TB, and is in many cases retreated as MDR-TB following a 
treatment failure.  The distribution of NTM in low resource countries with 
high burden TB prevalence remains unknown.  Meanwhile, cost 
information for the management of NTM in North America is based on 
data published in four available studies.  These studies offered a picture of 
direct medical costs for the outpatient management of NTM.  No cost data 
is available from Europe, Australia, or developed countries in Asia.  In the 
developing world, no data measuring cost or economic impact of NTM 
infection exists.  This lack of information exists alongside the mountains of 
published literature describing most every aspects of cost for TB in various 
countries including the industrialized west as well as developing countries 









CHAPTER 3: RESEARCH METHODS 
The rising cost of healthcare is an important field of interest in most 
every economy as balancing resource constraints with demand has 
become a common challenge in both developing as well as industrialized 
countries.  Understanding drivers of cost whether they be related to 
incidence or high treatment and technology costs has also become critical 
in resource management.  Further, the presence of trends in cost implies 
similar trends in disease incidence and associated management costs, 
which has important implications for scientific interest and policy 
interventions.  Given the lack of information available in peer reviewed 
published literature and national databases, Nontuberculous 
mycobacterium (NTM) disease remains an emerging field of research as 
little information is available regarding epidemiology and cost in virtually 
every care setting.  Despite this, the importance of NTM as a medical 
problem and cost driver remains undocumented.  Meanwhile, a myriad of 
data is available for Mycobacterium tuberculosis (TB) that qualifies this 
disease as a worldwide public health crisis, especially in select developing 
countries. 
This study was designed to add to the small knowledge base of 
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NTM, most specifically the cost and economic impact of this emerging 
public health challenge.  The cost and trends in cost of pulmonary NTM 
were evaluated in the context of similar data that was ascertained for 
pulmonary TB for hospitalized patients in the US over a long study period, 
from 2001 to 2012.  Additionally, this study sought to better understand 
demographic features of this disease as well as define and compare, and 
contrast social determinants of mycobacterial infection using national 
population level data.  Finally, clinical measures were recorded and 
evaluated comparing the impact of morbidity and mortality of pulmonary 
disease caused by NTM and TB. 
Study Goals 
The primary goal of this study is to conduct a comprehensive 
evaluation of the costs of care for pulmonary TB and NTM in US in-patient 
hospital settings using national data during a long study period beginning 
in 2001 through 2012.  The secondary goal of this study is to document 
cost data as well as identify important trends that may provide insight into 
future projections and challenges, as well as document the similarities and 
differences between these two diseases in demographic features, socio-
economic status and clinical outcomes.   
 Specific Aims 
This study has two very specific aims.  The first aim is to provide an 
accurate cost comparison of pulmonary disease caused by NTM and TB.  
The second aim is to identify and compare trends in cost, demographic 
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features and clinical outcome data of hospitalized patients with pulmonary 
NTM and TB. 
Hypothesis 
Current published medical literature provides significant insight into 
the epidemiology and cost of managing TB from various care settings all 
over the world.  Only a small percentage of this data is available for NTM 
infection, most of which is confined to care settings in North America.  
Based on published findings for both diseases, the expected results from 
this study include the identification of increasing rates of infection and 
related costs associated with the management of pulmonary NTM 
infection alongside flat or declining rates of pulmonary TB infection for 
hospitalized patients in the US.  Additionally, characteristic patient 
demographics for pulmonary TB infection including young males of lower 
socio-economic status as well as older females of higher socio-economic 
status for pulmonary NTM infection are expected to be found following 
review of this population-based national dataset.  
An alternate hypothesis is NTM rates and costs are represented by 
only a mild increase, which might be explained by the small amount of 
data currently available representing a sample that is not characteristic of 
population level national data.  Another explanation might be the limitation 
of scope in this study in which only hospitalized patients were considered, 
or that only select NTM pathogens could be included. 
 106 
 
Regardless of outcome, important implications for future research 
and policy implications can be extrapolated, including the continued 
worldwide investment in TB control and the increase in resources required 
for NTM control and research that may lead to better detection and 
appropriate treatment in all care settings.       
Methods 
 This is a retrospective, population based comparative study using 
data obtained from the National Inpatient Sample (NIS) available from the 
Agency for Healthcare Research and Quality’s Healthcare Cost and 
Utilization Project (HUCP).  NIS is the largest inpatient healthcare dataset 
in the US providing national estimates of hospital costs stratified by 
disease.  NIS collects data from every state participating in HCUP, which 
includes more than 95% of the US hospitalization data.321  All patients with 
a principal diagnosis of pulmonary NTM due to M. avium, M. 
interacellulare and M. kansasii and pulmonary TB who were discharged 
from the hospital during 2001 through 2012 were included in this study.  
This study was submitted to the University of Louisville Institutional 
Review Board, where it was determined that the data reviewed in this 
analysis did not meet the definition of human subjects and did not require 
a review from the ethics board in order to proceed.  The outcome letter for 
IRB study submission number 16.0828 has been included in the appendix.  
Study definitions 
This study includes both disease related definitions as well as 
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geographical features, payers and other socio-economic indicators and 
clinical measures.  Pulmonary NTM was defined by any hospital discharge 
associated with principal diagnosis of an International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9) code 031.0.  This 
diagnosis code includes pulmonary infection caused by M. avium, M. 
interacellulare and M. kansasii.  The Principal diagnosis was defined as 
the main reason for admission.  The regions of the US were classified into 
four zones recognized by Bureau of the Census as Northeast, Midwest, 
South and West as outlined below in Table 12. 
Table 12: Census Bureau Classification of the US by zone 
Zone States 
Northeast 
Connecticut, Maine, Massachusetts, New Hampshire, New 
Jersey, New York, Pennsylvania, Rhode Island, and 
Vermont 
Midwest 
Illinois, Indiana, Iowa, Kansas, Minnesota, Missouri, 
Michigan, Nebraska, North Dakota, Ohio, South Dakota 
and Wisconsin 
South 
Alabama, Arkansas, Delaware, District of Columbia, 
Florida, Georgia, Kentucky, Maryland, Mississippi, 
Louisiana, Tennessee, North Carolina, Oklahoma, South 
Carolina, Texas, Virginia, and West Virginia 
West 
Alaska, Arizona, California, Colorado, Hawaii, Idaho, 
Montana, Nevada, New Mexico, Oregon, Utah, 
Washington, Wyoming 
Several variables were defined, collected, and analyzed in this 
study related to disease severity, demographics and socio-economic 
status.  Hospital length of stay was defined as the number of days the 
patient remained in the hospital.  Payer was classified by the type of 
insurance coverage carried by the patient or lack thereof, which included 
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Medicare, Medicaid, Private insurance (Blue Cross, commercial carriers, 
and private HMOs and PPOs), uninsured which includes an insurance 
status of "self-pay" and "no charge", and Other which includes Worker's 
Compensation and other government payers.  Median income was 
defined as the average household income of patient zip code of residence 
and compared with national median income for the same year.  HCUPnet 
used value ranges of the average household income itemized by year.322  
Table 13: Annual ranges for calculation of median income by zip code  
Year Low Middle or Above 
2003 $1-35,999 $36,000+ 
2004 $1-35,999 $36,000+ 
2005 $1-36,999 $37,000+ 
2006 $1-37,999 $38,000+ 
2007 $1-38,999 $39,000+ 
2008 $1-38,999 $39,000+ 
2009 $1-39,999 $40,000+ 
2010 $1-40,999 $41,000+ 
2011 $1-38,999 $39,000+ 
2012 $1-38,999 $39,000+ 
 
Study variables 
Several variables in this study were evaluated; including age group, 
gender, region, payer, median income according to zip code, hospital 
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length of stay in days, mean hospital charge per admission, mean 
aggregated charge, total aggregated charge, and in-hospital deaths. 
Statistical Analysis 
The statistical significance of observed trends of NTM and TB 
national hospital costs were calculated using Poisson log-linear 
regression.  National hospital costs for NTM and TB were projected in 
relation to health care inflation for each year.  Expected mean aggregated 
charge (EaC) was calculated based on health care inflation using the 
equation, (EaC= Hci x OaC), in which EaC is expected aggregated 
hospital charge, Hci is health care inflation percent for each year (Hci = 
total aggregated hospital charge for a specific year divided by the total 
aggregated hospital charge for prior year ×100) and OaC is the observed 
aggregated charge for each medical condition.  A regression model was 
applied to test the correlation between observed and projected aggregated 
hospital charges, otherwise known as national hospital costs.  All 
statistical analyses were performed using SPSS statistical software 
(version 21.0, IBM Corporation)  
Results 
This study included an evaluation of 36,484,846 hospital 
admissions in the US from 2001 through 2012.  A total of 20,049 hospital 
discharges were reported for pulmonary NTM and 44,370 for pulmonary 
TB in the US from 2001 through 2012.  Using national data, this study 
measured numerous variables including demographic, cost and clinical 
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factors impacting the distribution of disease in the US.  The findings from 
this study have important implications that both validate and expand the 
findings from other research. 
 Demographic findings 
This study sought to explore demographic features of 
mycobacterial diseases in the context of new findings as well as published 
literature.  A number of demographic features of patients with pulmonary 
NTM and TB were measured including age, gender, payer status and 
estimated household income.  Demographic features of both diseases 
have been previously described relative to clinical and socio-economic 
importance, and the results of this study validated previous findings. 
The variation of age distribution for pulmonary mycobacterial 
diseases is well described in the literature.  These variations were also 
noted in the results of this study.  The majority of pulmonary NTM patients 
were between 65 and 84 years old (48.5%), while 70% of TB patients 
were younger than 65.  These findings were consistent with other studies 
as the association of NTM with older patients and TB with younger 
patients is well described.  When evaluating the over 65-age group 
specifically, a statistically significant difference was found between the 
NTM and TB group (P=0.0001) as well as the very elderly (+85) 
(P<0.00001, OR=2.83).  TB was also more common in pediatric 
populations than NTM, with 5.1% of hospitalized patients with TB 
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occurring in children 17 years and younger versus 1.2% of the population 
of hospitalized patients NTM occurring in children.  The table below 
illustrates the age distribution for each disease. 
Table 14: Age distribution of pulmonary NTM and TB  
Age Group NTM (%) TB (%) 
<17 (pediatric) 1.8 5.1 
18-44 7.6 36.3 
45-64 31.3 33.8 
65-84 (elderly) 48.5 20.7 
>85 (very elderly) 10.8 4.1 
The distribution of disease by gender demonstrated statistically 
significant differences between NTM and TB.  As described across 
studies, the relationship between TB and males along with that of NTM 
and females are well described in the currently available medical 
literature.  Pulmonary NTM was significantly higher in females than 
pulmonary TB (P<0.00001) and pulmonary TB is much higher in males 







Table 15: Gender Distribution of pulmonary NTM and TB 
Gender NTM (%) TB (%) 
Male 44 67 
Female 56 33 
One particularly interesting finding of this study is the geographical 
distribution of TB and NTM appear almost identical.  Both diseases were 
most common in the region defined as the South, representing 43% of 
cases for both diseases.   One explanation for this finding is that warm 
and humid climates may facilitate the transmission patterns of both TB 
and NTM similarly.  The next most common region was the West, which is 
also characterized by a warmer climate as compared to other regions in 
the US.  A total of 22% of NTM cases and 23% of TB cases resided in the 
West.  The Northwest represented the third most common region for NTM 
and TB at 19% and 21%, respectively.  Both diseases were least common 
in the Midwest.  These data indicate that all pathogenic mycobacterium 
species may be impacted by the same environmental factors that drive 
disease transmission. See the table below for the distribution of disease 






Table 16: Geographical distribution of pulmonary NTM and TB 
Region NTM (%) TB(%) 
Northwest 19 21 
Midwest 16 13 
South 43 43 
West 22 23 
Payer status was evaluated for TB and NTM admissions and the 
findings had several important implications.  The most significant 
difference in payers noted in the two groups was Medicare, representing 
61% of pulmonary NTM inpatient costs as compared to only 24% of the 
hospital costs of subjects with pulmonary TB (P<0.00001).  Given that 
NTM is associated with disease in older populations, the discovery that 
Medicare was the primary payer for NTM hospitalizations was expected. 
Medicare comprising 24% of TB admissions was higher than expected, 
but following reconciliation with the age distribution findings in this study 
these results were consistent with other findings from this study.  One 
explanation with the higher than expected percentage of TB patients from 
this age group may be a result of the baby boomer cohort occupying a 
large proportion of the population, which may amplify the distribution of 
less common diseases in this age group.  The association of TB with 
Medicaid and the uninsured, however, was fully expected given that these 
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payer statuses are strong markers for the poor, immigrants and other 
vulnerable populations.  The stronger association between NTM and 
private insurance was expected, implying a higher socio-economic 
association with NTM infection as reported in multiple studies.  See the 
table below for the distribution of disease by payer status. 
Table 17: Payer status of pulmonary NTM and TB 
Payer NTM (%) TB (%) 
Medicare 61 24 
Medicaid 10 23 
Private insurance 22 19 
Uninsured 5 25 
Other 2 9 
Missing 2 3 
For the purposes of this study, household income was defined by 
the average annual income of the zip code where the patient resided 
according to hospital admission records.  Income levels were defined by 
two variables: low and average or above.  These averages were adjusted 
annually based on inflation as outlined in Table 13.  Zip code analysis 
confirmed the association of NTM and higher socio-economic status as 
72% of NTM patients were defined as middle income or above.  This 
finding was in contrast with the demographics of patients with TB in which 
only 55% were considered average or above.  Only 26% of pulmonary 
NTM patients had a household income that was considered low as 
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compared to 41% for patients with pulmonary TB (P=0.0246, OR=0.51).  
These findings are consistent with those from other reports.  See the table 
below for disease distribution by median income based on zip code. 
Table 18: Median income by zip code in patients with pulmonary NTM and 
TB 
Median income for Zip Code NTM (%) TB (TB%) 
Low 26 41 
Middle or Above 72 55 
Missing 2 3 
Cost findings 
 Perhaps the most important finding of this study lie in the cost 
figures collected over the duration of eleven years, beginning in 2001 and 
continuing through 2012.  First, the total hospital cost for all conditions 
recorded during the study period was $1,337,939,745,325.  Pulmonary 
mycobacterial diseases accounted for a total of $2,981,880,609, which 
represents 0.22% of all hospital costs during the study period.  Hospital 
cost due to pulmonary NTM was found to be $903,767,292, which 
represents just over 30% of mycobacterial diseases diagnosed during the 
study period.  Hospital cost due to pulmonary TB was calculated at 
$2,078,113,317, which represents nearly 70% of mycobacterial diseases 
recorded during the study period.  See the table below for an illustration of 
hospital cost due to mycobacterial diseases from 2001 to 2012. 
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Table 19: Hospital charge due to mycobacterial diseases  
Indication Cost ($) Mycobacterial Diseases (%) 
NTM 903,767,292 30.3 
TB 2,078,113,317 69.7 
 The average hospital charges per admission were similar for both 
NTM and TB.  The mean aggregated charge describes the actual average 
annual hospital charges for both diseases, as opposed to the expected 
mean aggregated charge, which is a multiplier of actual hospital charges 
and healthcare inflation.  The expected mean aggregated charge was 
lower for both diseases than actual charges, which implies that trends for 
both diseases did not meet expectation in charges during the study period.  
However, these values are annual averages and do not reflect trends 
observed for both diseases during the study period.  Also listed below is 
the mean aggregated collection.  This figure is estimated based on 
assumed rates of collection for each payer.  These assumptions are 
based on industry averages which include the following: Medicare is 45%, 
Medicaid is 35%, private insurance is 55%, uninsured is 20%, and other 
and missing are estimated at 30%.  The overall average collection rate for 
NTM was estimated at 45% and for TB this rate was estimated at 37%.  
Please note that actual figures are not available as collection data are 




Table 20: Cost figures for patients with pulmonary NTM and TB 
Variables NTM TB 
Mean hospital charge per admission 
($) 47,120 48,332 
Mean aggregated charge ($) 
(OaC) 
80,886,935 246,398,995 
Expected mean aggregated charge ($) 
(EaC) 
85,005,570 282,501,149 
Estimated mean aggregated 
collections ($) 21,322 17,859 
Effective collection rate (%) 45 37 
Trend analysis in this study reflects a different result.  National hospital 
charges for pulmonary NTM increased at a statistically significant rate 
each year (P=0.001).  A linear regression analysis demonstrated a high 
degree of correlation between NTM observed and projected national 
hospital costs (R=0.938, P<0.001).  This finding predicts that NTM is on 
an upward trajectory that will likely continue to increase in coming years. 
However, no such correlation between observed and projected national 
hospital costs was found for pulmonary TB (R=0.284, P=0.372).  In fact, 
TB rates of infection appeared to increase, but did so at a rate less than 
healthcare infection.  Annual averages were likely impacted by movement 
early during the study period that did not maintain over time.  See the 
figure below for a representation of cost trends for mycobacterial diseases 





Figure 6: Mycobacterial diseases cost trends 
Epidemiological trends identified NTM and TB over time also have 
important implications for the future of mycobacterial disease.  Using 
admission data stratified by year for pulmonary NTM and pulmonary TB 
during the study period, an inverse relationship can be observed between 
the two causes of pulmonary mycobacterial disease.  TB incidence as 
represented by national hospital rates is on the decline during the study 
period while hospitalization due to NTM is rising.  See the figure below for 
a visual representation of the epidemiology of pulmonary NTM and 













Figure 7: Epidemiological data for hospitalizations due to mycobacterial 
diseases in the US 
Clinical Findings 
Finally, clinical outcome measures were recorded as a means of 
understanding the impact of mycobacterial diseases relative to morbidity 
and mortality.  A number of clinical measures were included.  First, 
hospital length of stay was recorded for both pulmonary NTM and 
pulmonary TB.  One interesting finding of this study was that TB patients 
had a longer hospital stay compared to NTM patients, TB averaging 13 
days versus 9 days for NTM but the mean hospital charge per admission 
was only marginally higher for TB as compared to NTM.  This finding 
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implies an average per diem hospital charge for NTM of $5,121.74 versus 
$3,580.15 for TB.  Another important outcome measure is mortality.  
Mortality was recorded for all hospital admissions in which the patient died 
during the hospital course.  The average death rate for NTM appears less 
in numbers than TB, but represents a higher percentage of patients.  This 
result is reflected by the lower number of NTM infections, but 
demonstrates a higher likelihood of mortality.  See the table below for 
discharge data and clinical measures for NTM and TB. 
Table 21: Clinical outcomes of patients with pulmonary NTM and TB 
Variables	   NTM 	   TB 	  
Pulmonary mycobacterial infection 
admissions	  
20,049	   44,370	  
Length of stay in days 	   9.2	   13.5	  
Average in-hospital mortality 
(mean/year)(percentage)	  
71 (35%)	   114 (26%)	  
Mean hospital charge per admission ($)  47,120 48,332 
 
Study Strengths 
 This was a population-based study that focused on the cost burden 
of inpatient care of patients with pulmonary mycobacterial diseases in the 
US between the years 2001 through 2012.  Overall cost was determined 
to be around $3 billion during the study period.  The aggregated hospital 
charges for pulmonary NTM had an increasing trend that was in the same 
trajectory with the health care inflation.  However, pulmonary TB inpatient 
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costs were not increasing at the same rate as the trajectory of health care 
cost inflation.  One could argue that the cost of managing TB during the 
study period was effectively decreasing.   
In addition to the measurement of cost, this study also identified 
important demographic features of both diseases.  Compared to patients 
with pulmonary TB, patients with pulmonary NTM were more often 
women.  The relationship between women and NTM is well described. 
Also, NTM patients were older and came from areas with higher incomes, 
which has been found in other studies.  In a 2014 review, Mirsaeidi and 
colleagues profiled a 70-year-old white female patient with pulmonary 
NTM as a typical case of NTM facilitating a discussion of NTM and 
females and the elderly.  The authors explained that the elderly are at an 
increased susceptibility to NTM pathogens and noted the unique treatment 
challenges due to health status and comorbidities.323  Another review 
noted the strong association between NTM and the elderly, 
immunosuppressed patients of all ages, HIV/AIDS, and the availability of 
solid organ transplantation as an option for treating a myriad of diseases.  
The authors of this review note that NTM rates continue to rise, which is 
likely related to both population features as well as advances in detection 
methods.  However, standards have yet to be established in management 
and treatment for most patients.  Better evidence based recommendations 
based on the availability of well-designed clinical trials is critical to the 
future management of the disease.324  A comparison study conducted in 
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Australia compared NTM isolates obtained in 1999 and 2005 along with 
clinical features.  This study found that NTM incidence increased from 2.2 
per 100,000 in 1999 to 3.2 per 100,000 in 2005.  This study also noted 
important demographic changes in the disease during the study period.  In 
1999, NTM was more common in middle-aged men who smoke while 
2005 identified the most common demographic were elderly women.325  
These findings are important for several reasons.  First, a recent 
population-based study demonstrated that females die more frequently 
from NTM and the majority (78%) of NTM-related mortality occurs in the 
patients 55 years of age or older.326 The association between elderly 
females and mortality were also confirmed in a study presented at the 
2016 IDSA meeting.327  Other demographic characteristics are also well 
described.  In a sample collected from Medicare Part B of patients with 
pulmonary NTM between the years 1997 and 2007, Adjemian and 
colleagues showed a relationship between the prevalence of disease in 
counties in the US with a higher median household income.  This study 
also identified the geographical distribution of disease using cluster 
analysis, noting that counties in warm areas like Louisiana, Florida and 
Hawaii were at a higher risk for pulmonary NTM as compared to counties 
in Rhode Island, Michigan, Minnesota and West Virginia.328  The findings 





This study measured hospital charges associated with pulmonary 
mycobacterial diseases in the US.  It is important to note that healthcare 
costs as represented by collections were estimated based on average 
collection rates per payer as actual collection rates are not available 
because this data is considered proprietary contractual information.  In 
addition to direct medical costs having been estimated, this study failed to 
capture a complete picture of economic impact as most every cost study 
does.  The full economic burden of mycobacterial disease, as is the case 
in almost every chronic disease, is very difficult, if not impossible, to 
measure.  In addition to the cost of delivering direct medical care in the 
inpatient and outpatient setting, total cost involves many other financial 
and human costs.  These costs may include lost wages, travel expenses 
and opportunity costs of the sick, the cost to administer public health 
programs including surveillance and prevention, and the economic impact 
on the family and social network of those receiving care for the disease.  It 
is important to note that the measure of total economic cost for any 
disease is outside of the scope of most studies. 
Another major limitation of the study was the use of ICD-9 billing 
codes as the search term for the database.  ICD-9 coding in this study has 
several important limitations.  First, while more than150 species of NTM 
have been identified as causes of disease in humans, ICD-9 billing only 
itemizes M. avium, M. interacellulare and M. kansasii.  Although these 
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species represent the most common cause of disease in humans in North 
America, an international average has recorded these species as a cause 
of human disease in only half of cases worldwide.329  Therefore, it is safe 
to assume that this study failed to capture a significant portion of NTM 
cases caused by other species, which leaves many unanswered questions 
regarding the true cost of care for patients hospitalized with NTM disease.  
Another important limitation associated with ICD-9 is that this study 
population only includes patients hospitalized with pulmonary 
mycobacterial disease.  TB and NTM can cause disease processes in 
most every part of the body including but not limited to skin and soft 
tissue, bone and joint, other major organs and disseminated disease.  
Although these cases are less common than pulmonary disease, they are 
more common particularly in immunosuppressed hosts and represent an 
important cost driver in the management of mycobacterial disease.   
This study was limited to inpatient cases of NTM and TB.  
Mycobacterial diseases are frequently managed in an outpatient setting 
given the chronicity and sometimes mild symptoms, so these cases of 
pulmonary NTM and TB were not considered in this analysis.  Further, it is 
not uncommon for NTM to be diagnosed in hospitalized patients following 
discharge given the slow growth of the pathogen in the laboratory.  
Therefore, patients with pulmonary NTM are assigned another billing code 
in these cases such as community acquired pneumonia, and were not 
included in this study.  In the event of a readmission, cases would be 
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coded correctly and only for subsequent admissions.  Therefore, all cases 
of pulmonary NTM due to M. avium, M. interacellulare and M. kansasii 
were not included in this study.  Given these important limitations, it is 
important to emphasize the cost of managing TB and especially NTM 

























CHAPTER 4: DISCUSSION 
 The purpose of this study was to determine the cost of care of 
managing two important diseases in the US.  Although the cost of TB has 
been extensively measured in a variety of care settings, this study offered 
another perspective of TB management cost in the US as well as 
identified important cost and epidemiological trends.  Also, this study 
contributed to the emerging cost data for the more elusive group of 
pathogens known as NTM.  Additionally, epidemiological and cost trends 
are identified in this study showing an increase in both.  This study offers 
important information establishing the importance of NTM for future 
research.  Further, the findings of this study have several important 
implications for public health policy. 
Implications for Policy 
  Globalization is a contemporary construct that describes the free 
movement of people, information, goods and services accessed across 
political and physical borders that separate countries, continents, cultures, 
religions, and societies.  Borders in the modern world are fluid as 
populations shift, information is shared, and economies are intertwined.  
Globalization also has important implications for health as global 
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connectedness is demonstrated by the exposure of disease by the 
interaction of populations with one another and a common environment 
like never before, leading the epidemiology of many diseases to be 
transformed into global public health challenges.  
 Policy makers who design and evaluate local and national health 
policy face many challenges due to the complexities and dynamics of 
influence from the outside.  A number of tools and frameworks are 
available to these experts that reduce the factors influencing a system and 
its drivers in order to identify opportunities to intervene and influence 
drivers that impact outcomes as a means of reaching program goals.  
Among these frameworks is the Ladder of Engagement, which offers an 
important decision support tool allowing policy makers to reduce complex 
systems to linear terms.  The Ladder of Engagement utilizes both Systems 
Thinking and Dynamic Modeling by identifying catalysts that drive human 
behavior over time.  Through the identification of nonlinear relationships 
represented by both positive and negative feedback loops, policy makers 
are able to isolate indicators of system behavior that represent 
opportunities for policy interventions that would enhance the ability of 
public health programs to be designed to reach policy goals.   
System Dynamics: Systems Thinking and Dynamic Modeling 
Critical to the process of System Dynamics is the use of two equally 
critical and consecutive steps: Systems Thinking and Dynamic Modeling. 
Systems Thinking provides the conceptual framework for establishing the 
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elements used in Dynamic Modeling, ensuring that the model is 
representative of the system so that accurate and reliable simulations 
occur.330  Systems Thinking alone provides an incomplete analysis of the 
process because the complexity of mental models exceeds one’s capacity 
to fully understand the implications without the process of model creation, 
mapping and simulation.  Just as Systems Thinking is dependent on 
Dynamic Modeling for providing advanced simulations and experiments 
predicting interactions and behaviors in a system, Dynamic Modeling is 
equally dependent on Systems Thinking to establish the model 
conceptually and represent the relationships and interactions accurately 
so that simulations and experiments precisely reflect the dynamics of the 
system.331 
Systems Thinking represents the first step in the process in which 
policy makers become oriented with the situation and capture the 
connection between parts and understanding their relationships to the 
functioning whole.  Although this step is considered qualitative, it does not 
represent a rejection of traditional scientific views built on mechanic and 
linear relationships.  Instead, Systems Thinking builds on these concepts 
with increased complexity rather than undermining them while requiring 
one to conceptualize systems as wholes as well as to precisely identify 
critical relationships and interactions that impact the whole.332 
Dynamic Modeling refers to the quantitative aspect of the System 
Dynamics that involves the use of models and simulations to increase the 
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understanding of policy makers of complex systems.  The opportunities for 
policy makers to use Dynamic Modeling to approach complex problems 
are significant as modeling represents a method of understanding change 
in a complex and dynamic system so that the influences within can be 
better understood and the direction of the system can be governed.  Also, 
mapping and simulation allows policy makers to identify potential 
opportunities within the system for the most effective policy interventions 
to optimally navigate system change.333  These experiments allow policy 
makers to input different policy interventions and better visualize 
outcomes relative to policy goals and those unrelated including 
unintended consequence as a means of evaluating policy prior to 
implementation.  Although the purpose of constructing these models is not 
to necessarily to allow policy makers to make predictions into the future, 
modeling does have the potential to shed insight into how behavior and 
interactions over time will impact the system.334  
The Ladder of Engagement 
System dynamicists possess a myriad of backgrounds and 
expertise as notable in the Center for Interdisciplinary Excellence in 
System Dynamics.  This diversity in background has led to the 
development of a collaborative model for approaching complex problem 
solving.  The Ladder of Engagement was developed and refined as a 
means of progressively and comprehensively understanding and 
describing complex interactions and behaviors in a system.  The model 
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consists of three separate but dependent levels: knowledge, 
understanding, and influence.   
Knowledge 
Critical in the knowledge segment of the Ladder of Engagement 
framework is knowing how a system behaves.  Therefore, defining the 
problem and developing an accurate and representative problem 
statement is the first step in the process.  This step is critical in identifying 
contributing factors to a problem situation and conceptualizing the 
relationship.  Also, the mapping process key in Dynamic Modeling is 
initiated as positions within the system, or stocks, are identified and 
defined relative to outcome stocks.  When mapping global public health 
problems, the most critical stocks in a system is death, and the positions 
within the system that flow directly into death may represent the problem 
situation. 
Understanding 
The next step in the Ladder of Engagement Framework is understanding.  
This step involves the identification and evaluation of leverage points in 
the system that can potentially drive behavior.  This too calls for 
conceptualizing relationships as part of the Systems Thinking process as 
well as building on the established model.  During this step, positions 
within the system are identified and represented by their role in affecting 
behaviors and outcomes within the system over time.  These positions are 
represented in the model as stocks.  Stocks that have an influence on a 
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desired outcome may identify opportunities in which this influence can be 
magnified.  Stocks that have an undesired outcome are identified as 
leverage points.  Opportunities to reduce the flow into an outcome stock of 
death exist in these positions. 
Influence 
This is the final step in the analysis in which policy makers 
determine whether the identified opportunities in the system are modifiable 
through policy change.  A systems dynamicist would likely employ the 
simulation phase of the Systems Dynamics process after policy 
development but prior to implementation to determine whether policy 
outcomes met policy goals and to identify resulting unintended 
consequences using the stock and flow modeling process.335 
Systems Dynamics and Public Health 
Systems Dynamics has been used to address public health issues 
since the 1970s.  Among these issues include disease epidemiology for 
both chronic diseases and infectious diseases, substance abuse including 
tobacco as well as illicit drugs, the movement of patients through the 
healthcare system including from emergency care to long term care 
facilities, healthcare resource capacity and delivery as conducted by 
HMOs, and the interactions between healthcare capacity and public health 
capacity in relation to specific disease epidemiology.336  The identification 
of public health issues appropriate for Systems Dynamics tools are 
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relatively easy to identify and, often times, the catalysts are likewise easy 
to isolate.337    
Systems Dynamics tools are being used in the surveillance of 
diseases in order to identify emerging pandemics and form response 
strategies.  The Centers for Disease Control and Prevention (CDC) 
possesses a well-established role in disease surveillance.  Using their 
proprietary system called BioSense, the CDC is able to feed 
epidemiological data into the system from local, national and even 
international sources to identify emerging and predict existing outbreaks of 
influenza.  This software allows the CDC to identify outbreaks sooner, in 
which case the organization is able inform and mobilize local health 
departments as well as policy makers so that the appropriate action can 
be taken to prevent further disease spread.  In this example, the CDC 
identified a potential influenza pandemic as a problem situation due to the 
1918 outbreak of the Spanish flu as well as the anticipated avian flu 
pandemic.  Mapping the problem and understanding epidemiological 
outbreak patterns associated with influenza led to the development of this 
simulation software to deliver predictions in real time.  Another example is 
the Laboratory Response Network, also managed by the CDC, which 
relies on an integrated system of laboratories that collect and feed data 
regarding communicable diseases and bioterrorism into a simulation 
program to allow for the rapid identification of a disease outbreak or acts 
of bioterrorism.  Additionally, the software provides decision support in the 
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formation of a response plan.338 
Despite the potential utility of Systems Dynamics to public health, 
many public health interventions in the US fall short of policy goals due to 
the inability of policy makers to approach problem situations holistically.  
The reason for this lies in the fragmented organizational and funding 
structure of public health.  As a result of these institutional barriers, public 
health is unable to assess and implement policy that addresses system 
wide catalysts.  Instead, policy is enacted in increments over time and 
often lacks the foresight and scope to address future complex problems.  
Therefore, public health is particularly in need of complex analytical tools 
to accurately and comprehensively address population level needs in the 
present and anticipate future needs by identifying and understanding 
trends over time.  Public health has seemingly settled for an incomplete 
analysis including only the conceptualization of complex problems, and 
this approach has proven incomplete with the absence of simulation 
studies.339  Although Systems Dynamics is particularly well suited for 
public health programs and interventions, institutional constraints in the 
US have acted as hindrances to the ability of state and local public health 
departments to explore System Dynamics tools in complex problem 
solving.   
Mycobacterium Tuberculosis 
Public health policy for Mycobacterium tuberculosis (TB) in the US 
has focused on prevention through screening, contact tracing and early 
 134 
 
treatment.  Despite institutional challenges, TB policy in the US has been 
very successful in preventing the transmission of disease within local 
populations.  These results have been shared in other industrialized 
nations.  Also, this preventative approach utilized in North America and 
Western Europe has been validated by systems dynamic modeling.  In a 
2011 Canadian study, a dynamic model was used to evaluate contact 
tracing and its role in the prevention of TB transmission.  In this model, the 
population was categorized based on risk status and health status and 
placed into one of ten stocks.  However, individuals who had been 
identified as an at risk contact under investigations through contact tracing 
were placed in the eleventh stock due to possible disease exposure.  The 
model illustrates transitions between stocks flowing in the upper part of the 
diagram downward to demonstrate the change in status relative to risk of 
infection over time.  Tian and researchers ran the model in this study, and 
their data supported the role of contact tracing in a theoretical closed 
community.  However, the findings of this study implied the expansion of 
the program currently being used in Canada could yield diminishing 
returns.  See the figure below for a visual representation of the model 




Figure 8: TB contact tracing model 
Despite the successes of TB control in many countries, TB remains 
an important cause of disease in select populations worldwide.  Among 
the consistent features of TB is its association with poverty.  Whether this 
relationship is observed in overall wealthy societies in which poor 
populations are disproportionately affected or poor countries in which the 
average population of impoverished citizens is affected, where one finds 
poverty is likewise where one finds TB.  The financial and economic 
burden in a variety of these settings has been well described in the 
 136 
 
literature.  However, policy challenges are looming in some care settings 
while others have had considerable success.      
In the developing world, a significant amount of research has been 
conducted on the economic burden and overall ramifications of disease to 
countries and its citizens in these care settings.  According to a systematic 
review, the average cost burden for those accessing TB treatment found 
across studies was as follows: 20% direct medical care, 20% indirect 
medical care, and 60% lost wages.  The WHO argues that programs 
designed to meet the needs of patients should address economic costs 
including the provision of direct costs, indirect costs, as well as lost wages 
of those with disease and their families and caretakers.341,342  Policy 
research agrees that without full economic support, TB patients may not 
be able to access TB treatment resources or complete treatment 
regimens.343  The impact of not ensuring patients have the resources and 
support to have access and be compliant with treatment on a global scale 
is arguably more significant than its cost.  The identification of TB in 
populations coupled with appropriate treatment hurdles cost exponentially 
by preventing further transmission and undermining the facilitation of drug 
resistance.      
 Systems dynamics can be applied to TB to this scenario using the 
Ladders of Engagement method.  In the underdeveloped world, two major 
undesirable outcomes exist.  The first is death, and TB as a cause of 
death is an important medical problem in most every country.  The other 
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undesirable outcome is drug resistant TB, which occurs through 
transmission from one person to another or occurs following inappropriate 
treatment.344  This initial model represents knowledge of the situation.  
Stocks that feed into these outcomes are treated and untreated TB, which 
represent an important opportunity for intervention according to most 
studies.  Assuring that diagnosed patients receive treatment is critical to 
TB control in most resource scarce high burden countries.  Not to say that 
the stock of patients who adhere to TB treatment do not have poor 
outcomes, but the stock that does not receive and complete treatment 
runs the highest risk for death as well as developing drug resistant 
disease.  This represents the second step, which establishes an 
understanding of the situation.  Barriers to treatment are mostly cost, and 
it is important to note that this population is usually unable to absorb any 
costs including direct medical care, indirect as well as lost wages without 
extreme hardship.  According to the literature, the total average patient 
costs in all care settings was equivalent to approximately one year of 
individual income.345  Therefore, the ability to access treatment represents 
the most critical barrier for this population and characterizes the most 
important opportunity for policy intervention.  Identifying opportunities as 
well as evaluating policy proposals prior to implementation occurs during 
this step.  It is also important to note that policy makers should fully 
understand the impact of policy relative to unmet needs and policy goals, 
in addition to the identification of unintended policy outcomes that may 
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influence the quality of the intervention.  
TB control efforts by public health have been successful in the 
developed world including the US.  However, these measures have only 
been effective in local populations as 64.6% of TB cases occurred in 
populations born outside the US.346  In the US, death secondary to TB is 
not as common as compared to outcomes in developing countries but TB 
policy has a much stronger emphasis on prevention.  Therefore, 
undesirable outcomes for policy makers include the disproportionate rate 
of infection in immigrant populations primarily from high TB burden 
countries.  The major contributing factor in the US is immigration policy 
itself, which also represents an important opportunity for policy 
intervention given that the target group can be screened for active and 
latent disease during the immigrations process.  According to policy 
researchers, universal screening for active disease using chest 
radiography has been widely disproven due to high cost and low yield.347 
Therefore, targeted screening has been proposed that limits the time and 
expense of chest radiography to migrants from high burden TB countries 
following face to face interviews in which risk profiles and clinical 
information are correlated.348  In this case, the stock of TB would be 
decreased with targeted screening more effectively and a lower cost than 
universal screening.  However, using the immigration process as a segue 
to TB control in select migrant populations limits the reach of TB control to 
legal migrants.349  Outreach to TB control in illegal immigrant populations 
 139 
 
could be accomplished through one of several methods.  First, a reduction 
in illegal immigration through increased border control could effectively 
reduce the number of new cases of TB in the US.  Another option is to 
amend immigration policy so that immigrants may enter the US legally and 
therefore be subject to the same processes as other migrants.  Both of 
these interventions would require widespread political support coupled 
with action from legislatures, which is unlikely given the controversial 
nature of immigration policy in the US.  Another option is to design an 
outreach program managed by public health specifically to reach illegal 
immigrant populations.  For this program to be successful, public health 
would be responsible for the identification of and significant relationship 
and trust building with invisible populations of illegal immigrants who often 
wish to remain invisible due to fear of discovery and deportation.  For 
illegal immigrants, the stock of TB would be decreased by public health 
outreach to these populations.  Policy research generally agrees that to 
tackle the issue of TB in foreign-born populations, a complex multi-system 
approach is necessary to targets at risk populations through various 
approaches. 
Nontuberculous Mycobacterium 
Having only been discovered in 1959, NTM is an emerging public 
health problem for which local and global policy has not been 
established.350  Despite this, NTM is an increasingly important cause of 
morbidity and mortality in the US and possibly the world.351  In fact, 
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evidence suggests that NTM is a more common cause of death in the US 
than TB.352  Key features of the disease make the formation of policy 
particularly challenging.  First, clinical signs and symptoms result in the 
disease being easily confused with TB in many health care settings,353 but 
epidemiology and modes of transmission are absolutely different.  
Therefore, effective policy that addresses NTM infection must be unique 
and not simply a modification of effective TB surveillance and control. 
In the developing world, NTM has been barely described.  
Therefore, the epidemiology of NTM disease in resource constrained care 
settings has not been published.  Some data indicate that NTM infection 
may be incorrectly labeled in many care settings in the developing world 
as drug resistant TB infection.  TB drugs being used incorrectly to treat 
NTM infection represents inappropriate antibiotic use and has important 
long-term consequences for the future of antibiotic effectiveness and 
short-term costs.354,355  It is also possible that in some cases, people in the 
developing world are co-infected with both diseases.  In these cases, 
initiating TB treatment only partially treats one infection leading clinicians 
to consider these patients a treatment failure and continue anti-TB drugs, 
or modify to second tier for supposed drug resistant TB.  Both of these 
scenarios also represent inappropriate antibiotic use as well as over 
utilizing healthcare resources.  It is also important to note that in the 
developing world, the epidemiological differences of affected populations 
and the geographical distribution of disease has not been established.  
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Therefore, these factors cannot be used for diagnostic support in the 
developing world.  Only through the use of laboratory techniques can NTM 
in this care setting be accurately diagnosed. 
The undesired outcomes for NTM are undiagnosed and 
misdiagnosed NTM disease.  When patients are being evaluated for TB, it 
is at this point that policy makers would suggest an intervention in which 
patients are diagnosed using laboratory methods that can accurately 
differentiate between different species of mycobacterium disease 
assuming access.  This is particularly challenging in some parts of the 
world in which laboratory methods are antiquated, infrastructure is subject 
to supply shortages including water and electricity, or TB is diagnosed 
without the use of laboratory methods in particularly resource constrained 
care settings.356  In these cases, the introduction of enhanced laboratory 
methods to identify cases of NTM infection might represent the 
establishment of new infrastructure, which may not be possible.  However, 
in countries with a high burden of drug resistance and HIV/AIDS, data 
establishing that these cases sometimes are misdiagnosed NTM could 
stimulate the demand for mycobacterium species typing if a significant 
portion of the TB control budget is being used for the treatment of drug 
resistant cases.  Therefore, policy makers must rely on more research in 
the epidemiology of NTM disease in developing countries before having 
the ability to measure the impact of policy interventions. 
NTM in the developed world is slightly more described.  First, 
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infection rates have been on a steady incline as demonstrated by reports 
in the peer reviewed medical research as well as this population-based 
study.357  Also, given its association with the elderly and immune-
suppressed hosts, the differing epidemiology in some cases allows the 
clinician to better identify NTM infection amidst TB infection.358,359,360  Also, 
accurate microbiological detection methods have been able to tease out 
NTM cases with the appearance of TB with remarkable accuracy.  
Currently, it remains unclear whether NTM rates are truly rising or the 
identification of NTM species coupled with the improvement of detection 
rates have resulted in the incline during the study period. 
Despite these questions, many researchers in the peer-reviewed 
literature believe NTM rates truly are increasing.  Among the explanations 
are population features in the US and much of the developed world that 
are uniquely different from those in the developing world.  First, the 
distribution of age in the US as well as many western European countries 
has resulted in a large segment of the population being considered 
elderly.361,362  As discussed, older age is an important risk factor for NTM 
infection.  Another important risk factor for NTM infection is suppressed 
immune status, which may result from a number of causes in the US 
including HIV infection, post-transplant therapy, immune modulating 
therapy, and cancer treatment.  This is also increasingly common in the 
US and is likely to also contribute to the incidence of 
disease.363,364,365,366,367,368  Another theory is the infrastructure of the built 
 143 
 
environment.  NTM is primarily transmitted from environmental sources 
including soil and water.369  Several studies have sought to identify 
specific modes of transmission in patients with confirmed NTM infection by 
confirming the presence of the same NTM species in water samples 
collected from their homes.  Researchers have demonstrated the pathway 
to transmission from water sources through the aerosolization of water 
from showerheads and hot tubs.  NTM has also been identified in public 
water sources.370,371  Further, some researchers have suggested that NTM 
is a result of the progress of modern societies as the disease is 
transmitted through the public water distribution infrastructure.372  Another 
possible pathway for NTM infection is in the food supply.373 
 In the US, the undesired outcome for policymakers is NTM 
infection.  As public health is well acquainted with employing measures to 
prevent the person-to-person transmission of diseases, measures to 
prevent disease transmission from the environment is largely uncharted 
territory.  Although the removal of NTM species from surrounding nature 
sources is not possible, preventing the transmission of disease from public 
water and food might be an opportunity for a policy intervention.   
Policy Recommendations 
 The purpose of this study was to better understand the emerging 
public health challenge of pulmonary NTM infection as presented in the 
context of the well-established public health challenge of the genetically 
similar pulmonary TB disease.  Using data methodology to compare the 
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cost of care and epidemiology of both diseases as well identify trends over 
time, this study confirmed the importance of pulmonary NTM as an 
increasingly critical public health challenge.  This designation leaves 
important questions for the future of this disease as well as the implication 
of public health policy intervention and further research. 
System dynamics can be an important decision support tool for the 
formation and evaluation of policy for select problem situations.  Ideally, 
the problem situation should be clearly definable given that the 
relationships and catalysts have been studied and identified and the 
dynamic behaviors that feed the causes and effects of these relationships 
are well understood.  Because transmission patterns for NTM disease 
remain elusive in the current body of medical research along with the 
incidence of disease in select population with identifiable risk factors 
seeming to occur sporadically, the cause and effect of this problem 
situation remain obscure.  This leaves many challenges for the formation 
of an effective intervention using this particular decision support tool.  
Therefore, much more needs to be learned about NTM from both a 
scientific and policy perspective in order to craft effective interventions that 
undermine the incidence of disease in populations in the US and 
worldwide. 
 Although systems dynamics may not be suitable for the evaluation 
of pulmonary NTM policy given that currently available data are limited, 
the mapping of not well understood problem situations can reveal 
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important implications for future research and the early formation of 
holistic policy.  Mapping may lay the foundations for defining important 
relationships leading to discoveries being made regarding the cause and 
effect of important interactions.  Also, opportunities for policy interventions 
may be revealed during this process, although in the absence of dynamic 
modeling they may not be testable.  In select situations in which policy 
interventions may be suitable despite the absence of ideal confirmatory 
data to support its efficacy, mapping alone may be an important step in 
the process of forming preliminary but effective policy.  Mapping may also 
identify what necessary data is needed to better understand a policy 
situation, which may be an important precursor to policy formation. 
The mapping of NTM as an emerging public health problem in the 
US reveals important opportunities for policy makers.  First and foremost, 
mapping demonstrates that not enough information is known about two 
very important aspects of NTM disease.  The first is epidemiology.  The 
distribution of NTM disease remaining unmeasured is a global problem, 
with the few data that exist having been pieced together from various 
studies that still only represents an unknown fraction of NTM cases.  The 
mapping of NTM along with current research also reveals that little is 
known about clinical aspects of NTM disease.  Considering that modes of 
exposure, transmission, and risk factors remain under described by 
current medical knowledge, the use of these variables in a model map 
only reveals to system dynamicists the information that remains 
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outstanding before proceeding to the next step.  In this case, 
understanding variables may represent key opportunities for policy and 
research.  See the figure below for a comprehensive map that represents 
the known relationship between NTM with risk groups and the 
environment. 
 
Figure 8: Mapping of NTM Transmission and Illness 
Given that so little is known about the epidemiology of NTM 
disease, the first important policy recommendation might be in the area of 
disease surveillance.  This might be achieved through the public health 
designation of NTM as a reportable disease.  Public health classifies 
select diseases as reportable that have been designated as particularly 
important public health problems.  In the US, diseases are reported to 
public health agencies in a variety of ways.  For some diseases it is 
mandatory for each case to be submitted by paper reports or by telephone 
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or even by computer, depending on the disease.  Gonorrhea is an 
example of a disease that is reported using paper forms whereas 
pertussis is reportable by phone.  In these cases, identifiable data are 
often collected in order to allow contact investigation.  Other diseases are 
reported to public health by proving a count of diagnosed cases.  Influenza 
is an example of a disease in which merely the number of cases 
diagnosed is reportable.374  All surveillance data are reported to the 
National Notifiable Diseases Surveillance System (NNDSS), which houses 
local, state, and national data managed by the CDC Division of Health 
Informatics and Surveillance (DHIS).  The DHIS submit, process and 
release data from the NNDSS to all levels of public health to support 
surveillance and analysis of disease distribution on all levels of 
government.375  The purpose of disease reporting to public health 
agencies is to provide local, state and national surveillance of important 
diseases in order to identify early trends in the occurrence of disease.  
The ultimate goal is to maintain a constant measure of disease distribution 
to gain a better understanding of baseline disease occurrence, prevent 
outbreaks as well as to undermine the natural trajectory of future cases.376 
The accuracy of national surveillance data for reportable diseases 
has been questioned.  In a 2011 study conducted in North Carolina, 
researchers found that complete reporting rates varied among the eight 
health care systems studied from 2% to 30%.  Also, of the fifty-three 
diseases evaluated, reporting completeness rates ranged from 0% to 
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82%.  The discrepancy in reporting did not seem to be related to the 
perceived public health importance of the disease in question.  Instead, 
diseases that were diagnosed through straight forward laboratory methods 
or clear clinical criteria were more likely to be reported than those that 
were difficult to identify clinically and/or involved multiple laboratory steps 
to establish a diagnosis.377  Also, physician knowledge regarding 
reportable diseases has likewise been questioned.  A survey study of 162 
emergency department physicians representing 34 states in the US 
indicated familiarity with IDSA guidelines for infectious foodborne 
pathogens, but did not demonstrate the same knowledge regarding the 
public health importance and reporting requirements.  Given that 
emergency departments represent primary care form so many Americans, 
this finding is of increased importance.378  
Recent federal legislation encouraging the use of information 
technology in healthcare has also sought to improve the rates at which 
notifiable diseases are reported.  The American Recovery and 
Reinvestment Act of 2009 in combination with the Health Information 
Technology for Economic and Clinical Health (HITECH) Act has 
encouraged widespread adoption of electronic health records by providing 
federal incentive funds to providers who adopt and maintain its use.  
Among the components of health record technology qualifying for 
incentive is the inclusion of disease surveillance and electronic reporting, 
which is expected to not only increase the rates of reporting, but also 
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reduce the number of errors and incomplete reports submitted with public 
health departments and the CDC.379 380  In a comparison study evaluating 
traditional reporting methods to the local health department with 
automated electronic laboratory reporting through a health information 
exchange, a total of 4785 reports for 53 reportable conditions were 
evaluated.  This study found that automatic electronic laboratory reporting 
identified 4.4 times as many cases as traditional reporting and did so on 
an average of 7.9 days sooner.381  Given the widespread adoption of 
electronic medical records secondary to HITECH, it is conceivable that 
automatic improvements in the availability of surveillance data for 
reportable many diseases may be an important policy outcome.  However, 
the WHO notes that the reporting of some notifiable diseases on an 
international level do not occur for a variety of reasons US.  First, some 
cases of disease may not be treated in a healthcare setting, but instead at 
home, in which case there would be no official record.  Also, reportable 
disease may not be diagnosed properly, which would undermine reporting.  
In these cases, the disease in question may be difficult to diagnose or the 
healthcare facility may not have adequate resources to make an accurate 
laboratory based diagnosis.  Also, reporting of notifiable diseases may be 
less common in under resourced healthcare settings despite the ability to 
make accurate diagnoses if employees are not educated or motivated to 
comply with reporting.  Finally, a fear of economic or political 
consequences may result in some diseases being intentionally not 
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reported.382   
NTM as a reportable disease would have several distinct 
challenges.  First, NTM is commonly confused with TB as they often 
present with similar clinical symptoms.  Also, NTM is diagnosed through a 
multi-step, slow laboratory process, which current research has shown 
would reduce the frequency of reporting.  Further, it is not uncommon for 
NTM to be diagnosed following hospital discharge, resulting in patients 
being managed for community-acquired pneumonia.  In these cases, is in 
uncertain how disease reporting would proceed as medical coding is 
rarely updated.  For these reasons, it is likely that designating NTM a 
reportable disease will still not provide a complete picture as is the case 
with many reportable diseases, but the designation of NTM as a 
reportable disease would vastly improve current available data on the 
disease.  
Another method of improving surveillance data for NTM disease 
involves piecing together currently available data sources.  Using national 
hospital data, as was the case in this study, provides one aspect of NTM 
epidemiology as well as the cost of care.  Combining these results with 
outpatient data that are available in the form of searchable datasets using 
ICD billing codes for each payer including commercial insurers and public 
payers could provide a more accurate epidemiological picture.  However, 
the collection of outpatient data would represent a laborious process to 
collect and analyze each individual dataset.  Given that research in the 
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field of NTM is likewise not being highly encouraged by the availability of 
abundant funding or significant scientific interest, the availability of said 
data that is matched with that of this study is not likely to be published.  
Further, the limitations of these data would be the same for this study, 
primarily the use of ICD-9 codes in which only three species of NTM was 
captured.  Finally, piecing hospital data with outpatient billing with 
searchable billing codes would offer a much closer-to-complete picture of 
NTM especially if ICD billing codes were to include more species of NTM, 
including a designation for other common atypical mycobacterium species. 
The table below outlines the current billing codes allotted for NTM 
infection. 
Table 22: ICD-10 Billing Codes for NTM Infection 
Atypical Mycobacteria 
A31.0 Pulmonary mycobacterial infection 
A31.1 Cutaneous mycobacterial infection 
A31.2 Disseminated MAC 
A31.8 Other mycobacterial infections 
A31.9 Mycobacterial infection, unspecified 
 
Since the ICD-10 update, pulmonary NTM remains only applicable 
to infections caused by M. avium, M. intracellulare, and M. kansasii.  Other 
NTM infections specified by current billing codes include cutaneous NTM, 
which refers to necrotizing skin and soft tissue infections caused by NTM 
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organisms M. marinum and M. ulcerans.  Also, disseminated disease 
caused by MAC is itemized alone.  Other mycobacterial infections are 
specified to include disseminated NTM caused by M. abscessus, M. 
chelonae, M. chelonei, M. fortuitum, and M. gordonae.  The final code 
designation applies to any other disease process caused by NTM and/or 
any other species of NTM.383  Although this represents an expansion of 
ICD-9, given the sheer numbers of NTM organisms as well as the 
potential for involvement of virtually any part of the body, relying on billing 
codes to define the presentation and distribution of NTM disease in the US 
might not be realistic.  
 Another important policy implication is, therefore, that research and 
scholarship in the area of NTM should be encouraged through the 
availability of national grants to facilitate a better understanding of this 
increasingly important cause of morbidity and mortality in the US.  Given 
that NTM is estimated to be a more important disease in the US than TB 
by several measures, it is questionable that more data continues to be 
generated in the various aspects of TB infection.  A study published by 
Raju and colleagues explains that as long as the NIH continues to largely 
ignore NTM as an important cause of human infection by supporting very 
few funded studies, NTM as an important cause of disease will continue to 
be under appreciated.384  Further, private sector interest in the treatment 
of most infectious diseases has been low for some time, given that 
research into chronic conditions for which long-term maintenance 
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medications are often prescribed represents a stronger revenue model for 
private sector research.  One important exception is HIV/AIDS, due to the 
chronicity of infection that results in lifetime treatment regimens for most 
patients.  Further, political support for research in the area of HIV/AIDS 
coupled with the willingness of the Food and Drug Administration to fast 
track new therapies has also stimulated private sector interest.  It is 
unlikely that NTM could rally similar support, but any discussion on the 
importance of NTM disease in the private sector could have an impact.  
Further, the single act of designating NTM as a reportable disease could 
facilitate both public and private sector interest, especially following the 














CHAPTER 5: CONCLUSION 
 Mycobacterial diseases are a global health problem, representing a 
source of an immeasurable and significant economic burden.  Describing 
infections caused by Mycobacterium tuberculosis (TB) and 
Nontuberculous mycobacteria (NTM), mycobacterial diseases represent 
important public health problems with significant health and economic 
consequences.  Both TB and NTM have many clinical presentations, but 
the most common manifestation of disease is pulmonary.  Also, both TB 
and NTM have a similar clinical picture along with characteristic nodules 
observable on lung imaging for pulmonary disease that is very distinct 
from other infectious diseases.  Despite similarities, TB and NTM differ 
dramatically in a number of ways.  In developing countries, NTM is more 
strongly associated with older hosts, particularly women, and those with 
underlying diseases that affect lung structure, undermine immunity, or 
those with medical conditions that require immune modulating therapies.  
TB, however, is associated with younger men, while comorbid conditions 
and unhealthy behaviors may also represent important risk factors.  TB is 
also strongly associated with vulnerable populations including recent 
immigrants from high burden TB countries.  In the developing world, the 
different demographic features of the two diseases are less described.  
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Given that emerging research indicates that the two diseases are often 
confused due to the similarities in clinical appearance coupled with a lack 
of available diagnostic tools that accurately differentiate between the two 
diseases, it is understandable that in some care settings how little is 
known about NTM relative to TB.  However, the misdiagnosis of 
subsequent inappropriate treatment of NTM as TB or drug resistant TB 
has important worldwide implications for both cost of care as well as 
clinical outcomes.  Also, inappropriate treatment has important 
consequences for the future treatment of mycobacterial diseases by 
facilitating drug resistance.   
One important similarity between the two diseases in most every 
care setting is the economic consequences of infection.  Mycobacterial 
diseases caused by both TB and NTM represent serious infections that 
require months of treatment along with routine monitoring to ensure 
clinical response to treatment.  Also, the risk of side effects due to 
extended antibiotic therapy is high and must be monitored along with 
treatment progress.  For patients and their families, the cost of medical 
care coupled with the economic cost of lost wages, travel and other 
expenses can be devastating for many in developing countries as well as 
for vulnerable populations living in poverty in developed countries.  Given 
that mycobacterial diseases have a strong association with poverty, the 
impact of disease on people and local economies can be catastrophic.  
Further, in some societies a diagnosis of mycobacterial infection can also 
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have personal consequences considering the stigma of disease.  This is 
particularly the case with TB infection as people have reported 
discrimination for employment, mate selection, and isolation from family 
and other important social networks.   
In the US, mycobacterial diseases represent a unique challenge.  
TB in the US has been successfully controlled following effective 
population based public health policy interventions focused on early 
identification and preventions.  Despite major challenges in TB care, 
including drug resistance and co-infection with HIV disease, rates have 
been stable and even decreasing in recent years in the US.  In local 
populations, the success of TB control can be better measured as rates 
have declined drastically.  In recent immigrant populations, the distribution 
of TB infection is disproportionately high, especially in immigrants from 
high burden TB countries.  Policy makers have suggested a number of 
programs focusing on immigrant populations as part of a multi-level 
approach to identify latent disease, active disease, and reaching both 
documented and undocumented immigrant populations.  NTM, however, 
represents an emerging public health problem with death rates on the 
sharp incline in the US.  Given that NTM tends to be associated with older 
populations with comorbid conditions commonly associated with aging, the 
current population structure in the US will likely continue to explain future 
increases in NTM incidence.  The cost of care for both diseases is likely to 
reflect these challenges.  
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 According to this study, the cost of care of managing mycobacterial 
diseases in the US between the years 2001 and 20012 was around $3 
billion.  During the study period, the aggregated hospital cost increased for 
both diseases.  For NTM, the increase in cost was at rate that exceeded 
healthcare inflation.  For TB, this increase was at a lower rate than 
inflation, which arguably represents a decline.  Also identified in this study 
were the unique demographic features of disease.  For example, the 
strong correlation between NTM and the elderly was observed, which is 
concerning given the aging population structure of the US.  As the large 
number of baby boomers enter their final years, the incidence of NTM is 
likely to demonstrate amplified increases, which could have a profound 
impact on healthcare costs.   
 For policy makers, this study has several important implications.  
First and foremost, NTM has been established as an emerging public 
health problem for which little is known.  The epidemiology of NTM has not 
been widely measured on a national or global scale.  The few data that 
exist are limited to select countries and care settings.  Even piecing 
together currently available knowledge does not begin to capture the 
actual distribution of NTM disease on a national or global scale.  As a 
result, the scope of the problem is not understood.  Further, many 
scientific aspects of the disease remain unknown.  Current literature has 
described various aspects of disease.  First, risk groups have been well 
described.  Also, the presence of infectious species in environmental 
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samples, water, and the food have been documented.  Further, NTM has 
found to be transmitted person to person in certain situations.  Despite 
ongoing research, little is known about how transmission occurs.  
Therefore, the policy implications for NTM as a public health challenge 
represent a different type of approach traditionally undertaken by public 
health.  With new diseases come new challenges that rival in importance 
to previous and successful public health policy.  The ability of public health 
to recognize emerging problems that may not resemble those of centuries 
past represents a true test of policy makers in their ability to recognize and 
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